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ABSTRACT 
 
 
This thesis presents the results of an investigation into the structural protein, tubulin, as a 
potential target for anti-trypanosomatid drug discovery and vaccine development. Recombinant 
α- and β- tubulin proteins from Trypanosoma brucei rhodesiense were expressed as soluble 
fusion proteins in an E. coli expression system. The recombinant α- and β- tubulins were used 
to determine the nature of binding of novel trifluralin analogues EPL-AJ 1003, 1007, 1008, 
1016 and 1017. Native tubulin from rats was used to determine the extent of binding to 
mammalian tubulin. The results of this study clearly demonstrate two important aspects of the 
binding of trifluralins to tubulin. Firstly, they have specific affinity for trypanosomal tubulin 
compared with mammalian regardless of the chemical composition of the trifluralin analogue 
tested. Secondly, they have a demonstrably stronger affinity for α-tubulin compared with β-
tubulin. In addition, compounds 1007, 1008, 1016 and 1017 have strong binding affinities for α-
tubulin, with limited binding affinity for mammalian tubulin, which indicates that these 
compounds selectively bind to trypanosomal tubulin.  
 
The morphology of bloodstream forms of T. b. rhodesiense exposed to trifluralin analogues was 
studied using electron microscopy and immunofluorescence to determine the ultrastructural 
changes these compounds induce as a result of binding to tubulin. All compounds tested 
induced severe irreparable damage in T. b. rhodesiense, including perturbation of subpellicular 
microtubules, extensive cytoplasmic swellings, axoneme and paraflagellar rod malformation, 
disconfiguration around the flagellar pocket and membrane disintegration. These results suggest 
that the mechanism of action of these trifluralin analogues is through the disruption of 
polymerization of tubulin into microtubules as a result of binding to α-tubulin.  
 
The potential for recombinant trypanosomal tubulins to be used as vaccine candidates was 
assessed by monitoring parasitaemia and length of survival of mice immunised with the proteins 
and challenged with a lethal infection of T. b. rhodesiense. Although all the mice vaccinated 
with recombinant tubulin developed a patent parasitaemia and did not survive, they were 
partially protected because their patency period and length of survival were significantly greater 
than the control groups. Furthermore, plasma collected from mice immunised with recombinant 
trypanosomal tubulin contained antibodies that recognized tubulin in a soluble extraction from 
T. b. rhodesiense. The results of this thesis confirm the potential for the structural protein, 
tubulin, to be used as a target for anti-trypanosomatid drug discovery and vaccine development. 
  v
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1.1  General Introduction to African Trypanosomiasis 
 
 
African trypanosomiasis is a complex and fatal neurological disease commonly called 
sleeping sickness in humans and nagana in domestic livestock. The causative agents for 
these diseases are species of the vector-borne flagellate protozoan Trypanosoma (Hoare, 
1970b). In sub-Saharan Africa tsetse-transmitted trypanosomiasis is mainly a disease of 
poor, marginalized and rural populations who depend on their land and labour for their 
livelihood. The most productive age group (15-45 years) are the most affected, which 
represents a major threat to economic development (WHO/AFRO, 2005). The estimated 
annual economic loss is U.S.$4.5 billion in terms of the cost of treatment, losses in meat 
production, milk yield and manpower plus the lost potential in livestock and crop 
production (Hursey, 2001; WHO/TDR, 2005). Trypanosomiasis is one of the most 
debilitating diseases in Africa.  
 
1.2  Classification of Trypanosomes 
 
 
African trypanosomiasis is caused by haemoflagellates of the genus Trypanosoma, 
subgenus  Trypanozoon and species Trypanosoma brucei, which includes three 
subspecies:  Trypanosoma brucei gambiense,  T. b. rhodesiense and T. b. brucei. 
Trypanosoma belong to the order Kinetoplastida, sub-order Trypanosomatina and 
family Trypanosomatidae (see Table 1.1) (Hoare, 1970b). The Trypanosomatidae are 
kinetoplastid flagellates, possessing  a single motile flagella that is either free or 
attached to the pellicle as an undulating membrane, a second flagellum represented by a 
barren basal body only and a small and compact kinetoplast containing DNA fibrils 
(Vickerman, 1970). All members of the Trypanosomatidae family are parasites in either 
invertebrate or vertebrate hosts, which are in contrast to other Kinetoplastids that may 
be free living (Molyneux and Ashford, 1983). Chapter 1. Introduction 
  3
Table 1.1  Classification of Trypanosomes 
 
 Order    Kinetoplastids 
 Family    Trypanosomatidae 
 Genus    Trypanosoma  
  Section   Stercoraria    Salivaria 
 Subgenus  Schizotrypanum  Duttonella  Nannomonas Trypanozoon Pycnomonas 
 Species   T. cruzi      T. vivax  T. congolense  T. equiperdum  T. suis 
        T .   e v a n s i    
        T .   b r u c e i  
Subspecies        T .   b .   r h o d e s i e n s e  
        T .   b .   g a m b i e n s e  
        T   . b .   b r u c e i  
 
 
 
 
1.3  Morphology and Biology of Trypanosomes 
 
 
Trypanosomes typically have a spindle-shaped flattened body which is usually curved. 
The part of the body which is directed forward during locomotion is described as the 
anterior end. The main structures of the trypanosomal cell are the kinetoplast, nucleus, 
basal body, flagellum and undulating membrane as shown in Figure 1.1 (Hoare, 1970a). 
 
 
 
 
 
Figure 1.1 Structure of a trypanosome a) kinetoplast, b) nucleus, c) basal body, d) 
e) flagellum-marginal and free portion, f) undulating membrane (Based on Hoare, 
1970a). 
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The major diagnostic feature of the order Kinetoplastida is the possession of the 
kinetoplast, which is a DNA containing organelle. The kinetoplast is disc-shaped and is 
situated at the base of the flagellum close to the basal body (Hoare, 1970a). The central 
part of the kinetoplast contains DNA that is composed of fibres densely packed in coils 
or figures of eight. The capsule of the kinetoplast is continuous with the mitochondrial 
membrane. From the inner membrane of the capsule cristae typical of the mitochondrial 
network are found extending into the matrix (Vickerman, 1970). This intimate 
association between the kinetoplast and the mitochondria is characteristic of 
trypanosomes and together, the two organelles are often called the kinetoplast-
mitochondrion complex (Molyneux and Ashford, 1983). 
 
The plasma membrane is typical in structure and similar to that of animal cells. It is 
approximately 2-4nm in width and consists of outer dense osmiophilic layers separated 
by a clear layer (Vickerman, 1974). The plasma membrane is covered by a 10-15nm 
thick surface coat, which contains two stage specific glycoproteins. The variant surface 
glycoprotein (vsg) is present in the bloodstream stage and procyclin (parp: for procyclic 
acidic repetitive protein) is present in the procyclic stage (Pays and Nolan, 1998). 
Beneath the plasma membrane is a series of pellicular microtubules that span 10nm in 
width and are separated by spaces 10-25nm in width (Molyneux and Ashford, 1983).  
 
The flagellum emerges from a basal body situated at the posterior part of the cell body 
(see Figure 1.1) and has a typical 9 + 2 structure of nine outer microtubule doublets with 
arms and two inner but separate microtubules (Molyneux and Ashford, 1983). The basal 
body is always found in close proximity to the kinetoplast and the distance between the 
two organelles remains constant throughout the life cycle (Vickerman, 1970). The 
flagellum runs forwards along the outer margin of a frilled fold of the pellicle, which 
extends along the length of the cell body and is known as the undulating membrane (see Chapter 1. Introduction 
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Figure 1.1). When the flagellum reaches the anterior end it either becomes free or 
terminates at the end of the membrane without a free portion (Hoare, 1970a). 
 
The nucleus is spherical or slightly ovoid in shape and is approximately 1.5-2.5μm in 
diameter. It is surrounded by a nuclear envelope consisting of two membranes separated 
by 18-25nm, which are punctured at varying intervals by nuclear pores. These nuclear 
pores are 65-100nm wide and physically link the cytoplasm with the nucleus (Molyneux 
and Ashford, 1983). Beneath the nuclear envelope, close to the inner nuclear membrane, 
is usually a thin layer of peripheral chromatin. The nucleolus is centrally placed and is 
0.5-1.0μm in diameter (Vickerman, 1974). 
 
The endoplasmic reticulum (ER) is continuous with the outer nuclear membrane and 
concentrated around the nucleus, which is similar to that of other eukaryotes. They may 
be rough (containing ribosomes) or smooth (without associated ribosomes). The ER is 
associated with subpellicular microtubules adjacent to the attachment zone linking the 
body of the parasite with the flagellum. The golgi apparatus is characteristically closely 
associated with the flagellar pocket and lies between the flagellar pocket and the 
nucleus (Molyneux and Ashford, 1983). 
 
 
1.4  Cytoskeletal Architecture of Trypanosomes 
 
1.4.1 Cytoskeleton 
 
 
The main components making up the trypanosomal cytoskeleton are the microtubular 
subpellicular corset, axoneme, basal body, paraflagellar rod, flagellum attachment zone 
and filaments responsible for parasite attachment to insect tissues (Kohl and Gull, Chapter 1. Introduction 
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1998). The highly cross-linked corset of subpellicular microtubule encircles the main 
cell body, determines the shape of the cell and is present throughout the complete cell 
cycle (Robinson et al., 1991). The single flagellum emerges from the posterior region of 
the cell and runs along the length of the cell body. It contains a classical 9 + 2 patterned 
axoneme. The paraflagellar rod is a highly ordered three-dimensional structure 
extending along and in close contact with most of the axoneme and is unique to 
trypanosomes (Hemphill et al., 1991a). 
 
 
1.4.2 Microtubules 
 
 
Microtubules are important structural proteins and are essential to all eukaryotic cells 
with functions extending from maintaining cell shape and cell division to cellular 
secretion and nutrient absorption (Lacey, 1988). There are more than 100 microtubule 
profiles forming the microtubular sub-pellicular corset. Microtubules are hollow, 
tubular organelles with an approximate lumen and outer diameter of 15nm and 24nm 
respectively. They are variable in length and are arranged helically along the axis of the 
cell with regular spacing of 18-22nm (Hemphill et al., 1991a).  
 
Microtubules compose the most prominant part of the cytoskeleton and are precisely 
cross-linked to form two defined structures. The main cell body is encircled by a highly 
cross-linked corset of subpellicular microtubules, which determines its shape and is 
present throughout the complete cell cycle (Robinson et al., 1991). Microtubules are 
linked to each other by a series of cross-bridges called microtubule-associated proteins 
(MAPs). The wide diversity of functions performed by microtubules in the cell is 
facilitated by the dynamics of polymerisation/depolymerisation and the interaction of 
tubulin with MAPs and motor proteins (Hirokawa, 1994). Chapter 1. Introduction 
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Microtubules are in constant dynamic equilibrium undergoing the addition and 
subtraction of soluble tubulin units at opposite ends of the developing tubule (Lacey, 
1988). Microtubules are polar and their two ends differ in their function. The so-called 
‘plus’ end is more active in assembly/disassembly whereas the opposite ‘minus’ end is 
less active in this process. The polarity of microtubules is essential for their function. 
The minus end is inserted into the centrosome, which is a microtubule-organizing centre 
(MTOC) and the formation and breakdown of microtubules are determined by the 
kinetics of assembly/disassembly that occurs at the plus end of the microtubule 
(MacRae, 1992). 
 
Microtubules are also aligned in neuronal axons so that direction-specific motor 
proteins such as kinesin (plus-end directed) and dynein (minus-end directed) transport 
organelles to specific regions in the cell. The regulation of microtubule dynamics by 
GTP hydrolysis and MAP binding, the interactions of tubulin with cofactors and the 
effect of post-translational modifications and isotypic diversity on tubulin function have 
been studied using a wide variety of biochemical and genetic techniques (Luduena et 
al., 1992). 
 
 
 
1.4.3 Tubulin   
 
 
Tubulin is the structural subunit of microtubules and constitutes 10% of the total 
proteins of Trypanosomes (Chan, 1994). The basic building block of the microtubule is 
the tubulin heterodimer consisting of α- and β- tubulin subunits. The αβ heterodimer 
bind head to tail into protofilaments. A series of 13 protofilaments interacting laterally 
comprise a microtubule (see Figure 1.2) (Lacey, 1988). Alpha- and β-tubulin from T. b. 
rhodesiense  comprise 451 and 442 amino acids respectively (Kimmel et al., 1985). Chapter 1. Introduction 
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Tubulin monomers are highly acidic with pI values of between 4 and 6 because 40% of 
carboxy-terminal residues are acidic (Lacey, 1988). 
 
 
Figure 1.2 Structure of a microtubule (Childs, 1996) 
 
 
The tubulin genes of the T. brucei genome are arranged in a cluster of 13-18 tandem 
repeated alternating α/β pairs (Kimmel et al., 1985; Seebeck et al., 1983; Stieger et al., 
1984) and contain no introns (Kimmel et al., 1985). This tubulin gene organization is 
unique in eukaryotes (MacRae and Langdon, 1989). The structural homology between 
α- and β-tubulin is normally >40% in all eukaryotic cells. They share 84-85% amino 
acid sequence homology with tubulin from mammals and 74-75% nucleotide sequence 
homology (Kimmel et al., 1985). Steiger et al. (1984) found, based on peptide mapping 
studies, that the amino acid sequence of trypanosomal α-tubulin was more similar to 
mammalian tubulin compared to trypanosomal β-tubulin.   
 
An important third member of the tubulin family is γ-tubulin. Gamma-tubulin is 
approximately 30% identical to α- and β-tubulin and is present in centrosomes and 
other MTOCs in eukaryotic cells (McKean et al., 2001). It has been shown to bind 
microtubule minus ends and thought to be responsible for mediating the link between 
microtubules and MTOCs (Li and Joshi, 1995; Rodionov et al., 1999). The γ-tubulin 
gene of T. brucei is present as only a single copy per haploid genome and the gene 
αβheterodimer
protofilament 
24nm Chapter 1. Introduction 
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product is estimated to be present at less than 1% the level of α- and β-tubulin (Stearns, 
et al., 1991). Recent studies have suggested that γ-tubulin is involved in maintaining the 
strong conservation of the 9 + 2 structure of the axoneme in T. brucei (McKean et al., 
2003). More recently discovered members of the tubulin family present in T. brucei 
include δ, ε and ζ. These members are not present in all eukaryotic cells and little is 
known about their function in T. brucei. However, there is a reasonable correlation 
between their occurrence and the presence of the motile axoneme and triplet 
microtubule basal body (McKean et al., 2001).   
 
Trypanosomal tubulin is modified after synthesis and incorporated into microtubules 
(Figure 1.2). These post-translational modifications include acetylation/deacetylation, 
tyrosination/ detyrosination, phosphorylation, polyglutamylation, polyglycylation and 
the generation of non-tyrosinatable α-tubulin (MacRae, 1997). Post-translational 
modification of tubulin can influence its assembly, the ability to bind MAP and the 
participation of microtubules in events such as cellular differentiation and 
morphogenesis (MacRae and Langdon, 1989). 
 
In contrast to eukaryotes, prokaryotes do not contain tubulin gene but instead have a 
similar gene called the filament temperature sensitivity Z (ftsZ) gene. The tubulin-like 
product of the ftsZ gene is FtsZ, a 7-amino acid tubulin motif which self assembles into 
a ring structure and functions as a cytoskeletal component (Bi and Lutkenhaus, 1991). It 
has been suggested that proteins ancestral to tubulins may have originated in bacteria 
prior to the evolution of eukaryotes (Bermudes et al., 1994). Although sequence identity 
with tubulin is only approximately 10%, FtsZ shares a glycine-rich segment that is 
considered the tubulin signature motif (GGGTGS/TG) (Nogales, 2000).  
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1.5  Vectors of African Trypanosomes 
 
 
African trypanosomes are transmitted via tsetse flies (Glossinids) which are Diptera of 
the family Glossinidae, genus Glossina (Pepin and Meda, 2001). In West and Central 
Africa, the Palpalis group of tsetse flies are responsible for transmitting T. b. 
gambiense. These are riverine species of tsetse and include Glossina palpalis, G. 
tachinoides and G. fuscipes. This group requires a sustained level of humidity and dense 
riverine habitats in order to survive. They prefer to feed on humans, who are the major 
reservoirs of infection, although wild and domestic animals play a minor role in 
particular foci of human African trypanosomiasis (Smith et al., 1998). 
 
In southern Africa the Morsitans group of tsetse flies transmit T. b. rhodesiense. These 
are savannah species of tsetse and include G. morsitans, G. pallidipes and G. 
swynnertoni. This group requires a drier environment in order to survive and live in 
open woodland areas. They prefer to feed on game animals and domestic livestock who 
are the main reservoirs for infection. Human infection occurs when people enter these 
areas, primarily poachers, hunters and gatherers and tourists (Smith et al., 1998). In East 
Africa T. b. rhodesiense is transmitted by the riverine species of tsetse, in particular G. 
fuscipes. The main reservoir of infection is domestic cattle, although human infection 
occurs in individuals living on farms or close to natural water sources (Pepin and Meda, 
2001). 
 
1.6  Life Cycle of Trypanosomes 
 
 
There are three developmental forms of trypanosomes that undergo cell multiplication: 
the non-infective procyclic, the epimastigote forms in tsetse fly and the long slender Chapter 1. Introduction 
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bloodstream forms (trypomastigotes) in mammalian hosts. The two developmental 
forms that do not multiply are the infective metacyclic form, which is the final stage in 
the tsetse fly and the short stumpy form in mammalian hosts (El-Sayed et al., 2000).  
 
When a tsetse fly feeds on an infected vertebrate the short stumpy forms that develop in 
the mammalian host travels with the blood meal into the crop and then into the lumen of 
the midgut. The developmental cycle in the tsetse fly takes 3-4 weeks depending on the 
external environmental conditions and the age and sex of the tsetse (Seed and Sechelski, 
1989). In the midgut of the tsetse fly the parasites develop into procyclics and replicate 
by binary fission (see Figure 1.3). The trypanosomes then develop their mitochondria, 
undergoes biochemical differentiation, change their surface coat to contain procyclin 
and begin dividing. From the midgut the trypanosomes migrate into the salivary glands 
where they develop into epimastigotes (see Figure 1.3). Epimastigotes are not infective 
to mammals and they attach to the epithelial cells of the salivary gland via their flagella 
and continue to divide forming microcolonies (Vickerman, 1985). When the population 
size of the microcolony reaches a certain density some epimastigotes transform into 
non-dividing metacyclic trypomastigotes by ceasing division, detaching from epithelial 
cells and acquiring a variable surface glycoprotein (vsg) coat. Metacyclic 
trypomastigotes are small, highly motile short stumpy forms which are infective to 
mammalian hosts (Seed and Wenck, 2003). 
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Figure 1.3 Schematic representation of the developmental cycle of T. brucei in the mammal and 
tsetse fly vector (Da Silva and Moser, 2003) 
 
 
 
When the metacyclic trypomastigotes are injected via the bite of a tsetse fly into the 
dermal connective tissue of a mammalian host they proliferate and cause a local skin 
reaction, called a chancre (Barry and Emergy, 1984). Trypomastigotes then enter the 
bloodstream via the lymphatic system and continue to divide by binary fission into long 
slender trypomastigotes (Figure 1.3). During high parasitaemia the trypomastigotes 
continue to divide by binary fission into long slender trypomastigotes (Figure 1.3). 
During parasitaemia remission, the short stumpy non-multiplicative form is abundant in 
order to conserve energy while infection continues in the mammal (Seed and Wenck, 
2003). 
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1.7  Pathogenesis of Human African Trypanosomiasis 
 
 
Human African Trypanosomiasis (HAT) is a debilitating disease and is characterised by 
two distinct phases; early and late (Molyneux and Ashford, 1983). The three subspecies 
of African trypanosomes are morphologically identical but differ in their ability to infect 
various hosts. T. b. brucei is a parasite of domestic and game animals and is not 
infectious to humans because it is lysed by a haptoglobin-like molecule present in 
human serum called human serum lytic factor (Smith et al., 1998). The subspecies T. b. 
gambiense and T. b. rhodesiense cause chronic and acute HAT respectively (Pepin and 
Meda, 2001). 
 
Following infection through a tsetse fly bite, trypanosomes proliferate at the site of 
infection resulting in a localized inflammation. A painful chancre usually develops at 
this site lasting 3-4 weeks (Barry and Emergy, 1984). During the first stage of disease 
the trypanosomes spread to the draining lymph node and bloodstream where they 
encounter the host immune system (Vickerman, 1985). Epitopes exposed on the surface 
of the vsg are readily detected by the host which leads to a humoral immune response. 
This results in the rapid clearing of the trypanosomes from the bloodstream. However, 
at any given time the trypanosome changes its vsg coat, resulting in new antigenic 
variants called variable antigenic types (VATs). This mechanism allows some 
trypanosomes to escape the antibody response directed against the previous vsg. The 
continuous interplay between the host immune reaction and antigenic variation of the 
trypanosome shapes the pattern of parasitaemia that is characteristic of trypanosomal 
infection (Pays and Nolan, 1998). 
 Chapter 1. Introduction 
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The ability of trypanosomes to change their surface coat appears to be the principle 
mechanism by which they survive in the host (Vickerman, 1974). Through regular 
changing of the vsg, the trypanosome exhausts the host immune system which is 
continuously being challenged to react to new surface determinants (Vanhamme and 
Pays, 1998). The genetic basis of the antigenic variation involves the switching of the 
gene coding for the vsg (Pays and Nolan, 1998). This means that the vsg is controlled in 
two ways; it is regulated throughout the life cycle and once the decision to turn on vsg 
expression is taken, populations expressing different vsgs succeed each other during 
infection (Vanhamme and Pays, 1998). 
 
As a result of the mounting immune response, the host experiences symptoms such as 
malaise, headache, nausea, transient fever and anaemia which are nonspecific and are 
easily confused with those from other diseases such as influenza and malaria (Hide, 
1999). However, enlarged submandibular lymph nodes, called Winterbottom's sign, are 
considered to be characteristic of early sleeping sickness (Burchmore et al., 2002). 
The late phase begins when the trypanosomes have invaded other organs including the 
central nervous system (CNS). This can occur within the first month of infection with T. 
b. rhodesiense or after months to years with T. b. gambiense infection (Burchmore et 
al., 2002). Trypanosomes can infect the CNS by crossing the blood-brain barrier. The 
blood-brain barrier (BBB) consists of endothelial cells separated by tight junctions and 
has selective permeability. The BBB separates circulating blood from the CNS and 
maintains the physico-chemical composition of the CNS by regulating the flow of 
compounds to and from the brain (Enanga et al., 2002). During the course of HAT the 
integrity of the BBB is compromised allowing the trypanosomes to invade the CNS. 
Until recently it was not clear whether trypanosomes were directly responsible for the 
weakening of the BBB or whether it was due to pro-inflammatory mediators responding Chapter 1. Introduction 
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to the parasite infection and causing lesions in the BBB. Recent studies have shown that 
human endothelial cells are directly activated by T. b. gambiense in vitro by enhancing 
the expression of surface molecules involved in cell adhesion, and the synthesis of pro-
inflammatory mediators (Girard et al., 2005). 
 
The invasion of the CNS by trypanosomes induces a cell-mediated immune response 
characterised by an infiltration of mononuclear cells with associated vasculitis and 
perivascular cuffing (Aloisi et al., 2000). The subsequent pathological lesions in the 
neural tissue results in the classical symptoms associated with HAT. These include 
sensory, motor and psychiatric disturbances (Poltera, 1985). Alteration of sleep pattern 
is the most characteristic clinical sign associated with this phase. The sleep-wake cycle 
becomes disorganized and fragmented which results in sleep episodes during the day 
and waking periods during the night (Lundkvist et al., 2004). Other neurological 
disorders such as tremors, delayed hyperaesthesia, ataxia and psychoses can also occur. 
Weight loss and endocrine abnormalities are also common symptoms. Brain function 
eventually deteriorates severely, resulting in coma and then death (Burchmore et al., 
2002). 
 
 
1.8  The Re-emergence of Human African Trypanosomiasis  
 
 
1.8.1  Distribution of Human African Trypanosomiasis 
 
 
Human African trypanosomiasis (HAT) occurs in 36 countries of sub-Saharan Africa 
within the “tsetse fly belt” which covers nearly 10 million square kilometres. Within the 
tsetse fly belt there are more than 200 active foci of HAT (WHO/TDR, 2001). 
Approximately 60 million people and 50 million animals are at risk from Chapter 1. Introduction 
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trypanosomiasis infection, mostly in rural areas. Only 7% of people at risk are under 
surveillance with regular examination or access to a health centre that can provide 
screening (Smith et al., 1998). Infection by T. b. gambiense occurs in West and Central 
Africa and infection by T. b. rhodesiense occurs in East and southern Africa. T. b. 
brucei occurs in livestock and wild game in all areas of the tsetse fly belt (Hide, 1999). 
 
In the early 1900's strict measures were introduced to control infection. These included 
the culling of wild animal reservoirs, clearing of vegetation that harboured tsetse flies 
and the screening of the human population for infection and treatment of those shown to 
be infected (Barrett, 1999). During the second half of the 20th century widespread civil 
disturbance and war, declining economies and reduced health financing caused the 
dismantling of disease control programmes. This has resulted in a dramatic resurgence 
of HAT in sub-Saharan Africa with T. b. gambiense infection spreading epidemically in 
large areas of central Africa especially in southern Sudan, the Democratic Republic of 
Congo (DRC), Angola, Uganda and the Central African Republic (Smith et al., 1998). 
 
The actual number of people currently infected with African trypanosomes is unknown 
because of underdiagnosis, especially in countries with a high prevalence of infection. 
The World Health Organization estimates that the current number of cases is between 
300, 000 and 500, 000 (WHO/TDR, 2005). The estimated number of new cases of HAT 
is approximately 100,000 per year (Pepin and Meda, 2001). In addition, Hursey (2001) 
estimated that the number of deaths caused by African trypanosomiasis is 100 people 
and 10,000 cattle per day. Reports from control programmes in individual countries can 
only give a rough estimate of the extent of this disease because the capacity to collect 
accurate national statistics varies between countries. This is mainly because it is often Chapter 1. Introduction 
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difficult to obtain accurate reports from some remote villages due to instability, civil 
war, and disruption of communication systems (Pepin and Meda, 2001). In some 
provinces of Sudan, the DRC and Angola the prevalence of HAT is as high as 20-50% 
and is the greatest cause of mortality ahead of AIDS (Ekwanzala et al.,  1996;   
WHO/TDR, 2001). Highly endemic countries where the prevalence is moderate but 
likely to increase include Cameroon, the Central African Republic, Chad, Côte d'Ivoire, 
Guinea, Mozambique, Uganda and the United Republic of Tanzania. Countries where 
the endemic level is low include Benin, Burkina Faso, Equatorial Guinea, Gabon, 
Kenya, Mali, Togo and Zambia. Countries whose present status is not clear are 
Botswana, Burundi, Ethiopia, Liberia, Namibia, Nigeria, Rwanda, Senegal and Sierra-
Leone (Pepin and Meda, 2001; WHO/TDR, 2001).  
 
1.8.2  Human African Trypanosomiasis in Angola 
 
 
HAT was first recognized as a health problem in Angola in 1871 (Abel et al., 2004). By 
1926 the Portuguese colonial government had created the first specialized unit for HAT 
control and in 1949 a national programme to control sleeping sickness was     
implemented (Stanghellini and Josenando, 2001). This involved the use of mobile 
health teams that visited each village at least once a year so that the entire population of 
Angola had access to diagnosis and treatment. This was effective in reducing the 
incidence of the disease and its mortality (Smith et al., 1998). 
 
In 1976, Angola became an independent country and experienced a devastating civil 
war that lasted 20 years. This caused the complete collapse of all treatment programmes 
and the re-emergence of sleeping sickness as a major cause of mortality (Smith et al., 
1998; Stich et al., 2003). In 1974 only 3 new cases were reported compared to 2001 Chapter 1. Introduction 
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when over 12,000 new cases were reported (Stanghellini and Josenando, 2001; Stich et 
al., 2003). During times of war the Catholic Church has held privilege to reach both 
sides of conflict in order to carry out certain operations. In 1996 the church began an 
HAT program named ANGOTRIP (an acronym combining the two Portuguese words 
for Angola and trypanosomiasis) which involved setting up treatment centres equipped 
with health professionals to treat infected individuals, mobile teams of professionals to 
actively seek infected individuals in remote villages and Lancien  type traps along 
riverbanks, water holes, farms and other tsetse infested areas to control vector 
populations (Abel et al., 2004). This has helped manage HAT in some areas in Angola 
however, continuing civil war continues to obstruct efforts to control the problem (Abel 
et al., 2004; Stich et al., 2003). In 2003, 3,000 new cases of HAT were reported to the 
WHO from Angola (WHO/AFRO, 2005). 
 
1.8.3  Human African Trypanosomiasis in the Democratic Republic of Congo 
 
 
The first significant outbreak of HAT occurred in the Belgian Congo (now the 
Democratic Republic of Congo [DRC]) during the 1920’s and it took several decades 
and a large scale sustained effort to control the disease.  The number of cases was 
reported to be 33,502 in 1930, which dropped to 11,837 in 1940 and continued to 
decrease over several decades (Van Nieuwenhove et al., 2001). This decrease was due 
to the concerted effort of mobile teams that screened the population every 6 months and 
administered treatment to those shown to be infected. By the 1950’s the number of 
mobile teams reached 250 and in 1959 the number of reported cases was only 1,000 
(Ekwanzala et al., 1996). 
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In 1960, the Belgian Congo became Zaire, an independent country. HAT control efforts 
ceased because of civil unrest, which resulted in poor road conditions, widespread 
corruption and poorly paid unmotivated staff. Increasing instability in the area resulted 
in a devastating civil war that continued until 1967.  Epidemics of trypanosomiasis 
emerged once again (Ekwanzala et al., 1996). New control efforts began in 1965 
supported by Belgian technical and financial assistance. The control programmes 
continued until 1990. During this time 30 mobile teams were operating and helped 
stabilise the incidence to approximately 5-10, 000 new cases per year. During 1994 to 
1996 the number of cases increased to more than 19,000 (Smith et al., 1998). According 
to Ekwanzala et al (1996), the true number was most likely double that figure. The 
current level of disease has reached levels comparable to those seen in the early 1930’s 
with the number of infected individuals in 2001 exceeding 100,000 (Van Nieuwenhove 
et al., 2001). In 1998, approximately 2% of the total population of the DRC were 
affected and in some communities the prevalence was as high as 70% (Barrett, 1999). In 
2003, 11,000 new cases of HAT were reported from the DRC to the WHO 
(WHO/AFRO, 2005). 
 
 
1.8.4  Human African Trypanosomiasis in Uganda 
 
 
From 1901 to 1916 there were massive epidemics of HAT in Uganda, which resulted in 
250,000 deaths (Smith et al., 1998). After this time the disease became confined to a 
few discrete foci with the major focus being in the Busoga region. This region remains a 
significant focus for sleeping sickness today (Hide, 1999). During the 1940's an 
epidemic emerged due to civil war, insecurity and deteriorating economic circumstances 
(Smith et al., 1998). In addition, changes in agricultural practices led to vegetation 
changes in areas where cotton was produced which resulted in the overgrowth of Chapter 1. Introduction 
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Lantana camara, that supported large populations of G. fuscipes fuscipes (Abaru, 1985). 
Between 1976 and 1990 there were 40,000 confirmed cases in the Busoga district and a 
further 6,000 in neighbouring areas with people dying within three months of initial 
infection (Smith et al., 1998). Uganda is the only country to have endemic foci of both 
T. b. gambiense in the northwest and T. b. rhodesiense in the southeast of the country 
(Abaru, 1985). 
 
In 1985 control programmes were initiated and health centres were equipped to 
diagnose HAT and provide treatment. These programmes helped decrease the 
proportion of late stage patients admitted to hospital from 80% to 25% (Pepin and 
Meda, 2001). Furthermore, the increased surveillance enabled epidemic areas to be 
more accurately defined. By 1998 the number of notifications of the disease was less 
than 20 per month (Smith et al., 1998). A recent outbreak of T. b. rhodesiense infection 
occurred in 2001 outside the defined foci in the district of Soroti and was found to be 
associated with the importation of infected cattle from areas where the disease was 
endemic (Fevre et al., 2001). As a result of this, 133,000 people have been put at risk of 
infection and in 2004, 428 new cases were presented at the only health facility equipped 
to diagnose and treat the disease in Soroti district. Of these cases, 18 people died at the 
facility. It was also estimated that a further 299 cases were unreported based on a 
deterministic model (Fevre et al., 2005). 
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1.9 Vector  Control 
 
 
1.9.1  Methods of Vector Control 
 
 
The control of the tsetse fly vector is an important component of programmes to reduce 
the incidence of HAT (Allsopp, 2001). The first method of controlling tsetse flies 
involved the slaughter of game animals and clearance of large areas of woodland in 
order to deprive tsetse flies of food and shelter. This was quickly considered to be 
environmentally unacceptable and it was during the 1940's that insecticides came into 
use. Ground spraying of persistent insecticides such as DDT, dieldrin, endosulfan or 
synthetic pyrethroids became the primary method for controlling tsetse fly populations 
for over 40 years. Ground spraying of insecticide enabled the eradication of tsetse flies 
from thousands of square kilometres of land including 230,000km
2 in Nigeria alone 
(Pepin and Meda, 2001). Aerial spraying of residual insecticides also began during the 
1940's, which was successful in South Africa and combined with ground spraying kept 
trypanosomiasis under control in Cameroon for 18 years (Allsopp, 2001). During the 
1940's, large scale sequential aerial applications of low-dosage, non-residual aerosols 
(sequential aerial technique, SAT) were evaluated in Zambia. SAT became the method 
of choice for trypanosomiasis control in Botswana for 20 years and was also carried out 
in Zimbabwe, Ivory Coast, Somalia, Nigeria and Uganda (Allsopp, 2001). 
 
Currently, the most widely implemented method for tsetse control is the bait technique 
using visual or olfactory attractants to lure tsetse flies in order to trap or kill them. The 
most commonly used trap is the bi-conical trap which was developed in the early 1970's 
(Holmes, 1997). This trap when impregnated with a mixture of acetone, octenol and 
cow urine is very effective in trapping tsetse flies (Belete et al., 2004). Chapter 1. Introduction 
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More recently, cloth screens impregnated with insecticide (targets) have replaced the 
more traditional cone-shaped traps. Blue and black coloured cloth and attractants such 
as carbon dioxide, acetone, and urine phenols were found to be effective in luring tsetse 
to the target where the applied insecticide killed the flies on contact (Schofield and 
Maudlin, 2001). Insecticide-impregnated traps and targets require only a fraction of the 
insecticide compared to aerial spraying. Insecticide-impregnated targets are more 
effective and cheaper than traps, although the display of dead tsetse flies in traps helps 
motivate local people to participate in their use (Holmes, 1997). Traps baited with 
attractants have been successfully used in Ethiopia (Belete et al., 2004) and Tanzania 
(Kasilagila, 2003). A new multipurpose fly trap, the Nzi trap, consisting of cloth with 
blue and black panels and netting to trap the flies has also been used effectively in 
Kenya (Mihok, 2002). 
 
Insecticide treated cattle can also be used as live bait. Pour-on insecticides such as 
synthetic pyrethroids are highly effective in killing tsetse whilst exhibiting low 
mammalian toxicity (Allsopp, 2001). Traps, targets and bait technology are particularly 
suitable for community based control programmes with relatively cheap materials and 
unsophisticated technology. However, traps and targets require regular supervision to 
reduce damage and theft and their effectiveness varies between species and geographic 
subspecies of Glossina (Holmes, 1997). 
 
A recent development in tsetse control is the sterile insect technique. This method 
involves sterilizing male tsetse flies by irradiation and releasing them by light aircraft in 
affected areas. The males engage in sterile intercourse with females. The tsetse 
population density is first suppressed, usually with insecticides, before the release of the 
sterile male tsetse. A plan was announced in 2000 by the International Atomic Energy Chapter 1. Introduction 
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Agency (IAEA) to implement a continent wide release of sterile tsetse in order to 
eradicate tsetse flies completely from Africa (Stich et al., 2003). This programme 
involved dispersing flies twice weekly across specific flight lines spaced by a distance 
of 1-2km. More than 8.5 million flies were released this way from August 1994 to 
December 1997 and resulted in the eradication of tsetse flies from the island of Zanzibar 
(Vreysen et al., 2000).  
 
The African governments have recently developed a new initiative, titled the Pan 
African Tsetse and Trypanosomiasis Eradication Campaign (PATTEC), which aims to 
eliminate tsetse flies from mainland Africa completely. PATTEC was derived from a 
decision made by the African Heads of State and Government at the 36th summit of the 
Organisation of African Unity (OAU), to 'act collectively and rise to the challenge of 
eradicating tsetse flies from the African continent in the shortest time possible' (Kabayo, 
2002). The plan of action utilises all available control methods in order to eradicate 
tsetse flies from pockets of infestation at a time. Tsetse-free zones are aimed to be 
created in this way which will then be linked over larger areas. The governments of 
Ethiopia, Mali, Burkina Faso, Botswana, Kenya, Uganda and Tanzania have begun to 
implement the plan in selected areas of their respective countries (Kabayo, 2002). 
 
A more recent development is the launch of a five-point strategy by WHO to eliminate 
most cases of HAT by 2015. The strategy includes the implementation of national 
sleeping sickness policies in 80% of African countries where the disease is widespread 
by 2007, and training enough staff to work on disease control by 2008. In addition, 
targeted vector control interventions are aimed to be in place by 2012 (WHO/AFRO, 
2005).  
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1.9.2  Problems Associated with Vector Control 
 
 
The main problem with existing tsetse control methods as with many operations in 
Africa is sustainability. Reinvasion of tsetse flies is inevitable unless the entire 
population of tsetse is eliminated or cleared areas are protected (Schofield and Maudlin, 
2001). During times of civil unrest and associated lack of finance maintaining tsetse 
control programmes becomes a low priority. As a result of this almost all major tsetse 
control campaigns implemented during the 20th century have ultimately failed (Allsopp, 
2001). This is primarily the reason why PATTEC's proposal has been met with much 
scepticism and criticism from other scientists. It has been viewed that the proposal is 
overly ambitious and that it may have been more feasible to implement a control 
strategy rather than complete eradication. The success in eradicating tsetse flies from 
Zanzibar is not considered a good model for the mainland because it is a small island 
that is isolated from the mainland of Africa by 30km of water (Rogers and Randolph, 
2002). The success of this campaign relies heavily on the concerted participation and 
dedication of international agencies and all African governments, which taken from the 
history of HAT in Africa, is highly unlikely.    
 
1.10 Vaccines 
 
 
Currently there are no available vaccines against African trypanosomiasis and prospects 
for the development of a vaccine are considered to be very poor (Seed, 2001). This is 
mainly due to the ability of trypanosomes to undergo antigenic variation, where they 
periodically switch their vsg coat to evade the host immune response. When designing a 
vaccine, proteins present on the cell surface of the target organism are usually exploited 
because these proteins are most accessible to the host immune cells. Since 
trypanosomes have the ability to switch their vsg surface coat, they can escape the Chapter 1. Introduction 
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antibody response directed against the previous antigen rendering a vsg vaccine useless 
(Barbet and McGuire, 1978; Donelson et al., 1998). Despite this, partial protection 
against T. brucei infection has been reported in cattle immunised with viable irradiated 
T. brucei where antibodies elicited by irradiated trypanosomes were found to be specific 
for antigenic determinants on the vsg exposed on the surface of live trypanosomes 
(Morrison et al., 1982). 
 
 Invariable trypanosomal components have recently been studied as potential vaccines 
against trypanosomiasis. Cattle were partially protected from T. congolense and T. vivax 
infection when immunized with flagellar pocket antigen from T. b. rhodesiense 
(Mkunza et al., 1995) and mice were fully protected against trypanosomiasis infection 
when immunized with a vaccine comprising trypanosomal microtubule-associated 
proteins p15 and p52, with aldolase and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (Balaban et al., 1995; Rasooly and Balaban, 2004). In addition to this, mice 
vaccinated with native trypanosomal tubulin were also shown to be fully protected from 
T. brucei (Lubega et al., 2002a). Mice immunized with paraflagellar rod protein 
conferred full protection against T. cruzi infection (Miller et al., 1996; Wrightsman et 
al., 1995). 
 
 
1.11  Treatment of African Trypanosomiasis 
 
 
1.11.1  Current Treatment Regimes for Human African Trypanosomiasis   
 
 
Current treatment regimes for HAT rely on a limited number of drugs developed several 
decades ago and little progress has been made in developing new drugs in the last fifty 
years with the exception of Eflornithine, which was developed in 1990. There are many Chapter 1. Introduction 
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problems associated with current drugs including resistance, toxicity and a lack of 
guaranteed supply (Barrett and Barrett, 2000). Toxicity is a major problem, with all the 
drugs inducing side effects of varying severity partly because they were developed prior 
to the introduction of modern regulatory requirements with respect to toxicity, with the 
exception of Eflornithine (Barrett and Barrett, 2000). These drugs would probably not 
have received licenses if they were introduced today (Barrett and Gilbert, 2002). 
 
Infectious diseases are considered neglected when there is a lack of effective, affordable 
or easy to use drug treatments (Yamey and Torreele, 2002). People in developing 
countries are too poor to buy drugs and are therefore, largely ignored by the 
pharmaceutical industry (Veeken and Pecoul, 2000). Of 1393 new drugs marketed 
between 1975 and 1999, only 16 were for neglected diseases (Trouiller et al., 2002). 
The lack of profit and the difficulties in synthesizing current drugs have caused some 
manufacturers to abandon production of certain drugs. The production of Eflornithine, 
for example, ceased in 1995 by its original supplier Marion-Merrell-Dow, which left the 
WHO searching for a new supplier (Barrett, 2000). Over the past decade the WHO, with 
vigorous support from Médecins sans Frontèires (Drugs for Neglected Diseases 
Initiative), have increased their efforts in campaigning for the continued production of 
current anti-trypanosomatid drugs (Veeken and Pecoul, 2000) and to promote research 
into developing new drugs for the treatment of HAT (Etchegorry et al., 2001). As a 
result of the campaigning the pharmaceutical company Aventis have guaranteed to 
produce Eflornithine, Melarsoprol and Pentamidine for at least 5 years and Bayer will 
continue to produce Suramin indefinitely (WHO/TDR, 2001). Moreover, the WHO and 
the public sector have created favourable marketing conditions persuading industry to 
enter public-private partnerships to tackle neglected diseases such as malaria, HIV and 
tuberculosis.  Chapter 1. Introduction 
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The best strategy for ensuring maximum efficiency in treating those infected with 
trypanosomes is early diagnosis. This is not always feasible, nor is it currently possible 
to avoid the need for a lumbar puncture to establish the diagnosis by examination of the 
cerebrospinal fluid (CSF). Lumbar puncture requires trained medical staff to carry out, 
is invasive and often painful (Bouteille et al., 2003). The criteria currently used for 
diagnosing HAT are a high leucocyte count in the CSF (>5 cells/μl) or an increase in 
CSF protein (>37mg/100ml according to the colorimetric method) with the chance 
detection of trypanosomes in the cell counting chamber. The problem with following 
these criteria is that evidence of trypanosomes is not necessary to make a diagnosis of 
infection. This makes the test non-specific as other CNS infections may cause high 
leucocyte counts in the CSF. In addition, the test is not standardized which makes them 
unreproducible (Bouteille et al., 2003).  
 
Research into improving diagnosis of CNS involvement in HAT have shown promise, 
with the finding that trypanosomiasis related immunoglobulin patterns are of value in 
differential diagnosis. It was proposed that CNS involvement is diagnosed only in 
patients with >20 cells/μl or with intrathecal IgM synthesis (Lejon et al., 2003). 
However, sufficient evidence of the efficacy of the suggested diagnostic test is yet to be 
determined. Initial diagnosis in the field still relies on the detection of trypanosomes, 
most often with insensitive techniques that have been used for decades. Thick blood 
smears are usually adequate for initial screening for T. b. rhodesiense infection as 
parasitaemia is readily detected in the peripheral blood, especially in early infection. 
However, with T. b. gambiense infection parasitaemia is usually low and too variable 
for blood smears to be an accurate diagnostic technique. Lymph node aspiration is a 
common technique for diagnosing early T. b. gambiense infection but requires trained 
medical staff to perform them (Smith et al., 1998).  Chapter 1. Introduction 
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Other existing problems with current trypanocidal drugs involve administration and 
supply of the drug to infected patients. All current trypanocides, with the exception of 
pentamidine, must be administered by intravenous (i.v) injection and their use is 
associated with severe side-effects. In addition, the economic instability, deterioration in 
transport and the public health infrastructure in some epidemic countries, makes it 
virtually impossible to deliver these drugs (Barrett, 2000). Currently no trypanocide can 
be administered orally, which means mass administration to areas of need is 
problematic. In addition, the potentially life threatening side effects that occur with 
treatment for late-stage trypanosomiasis means that hospitalization of patients is often 
required for a full month (Gutteridge, 1985). Resistance is also rapidly becoming a 
problem in the field. The relapse rate in patients treated with melarsoprol in Angola, 
Southern Sudan, DRC and northern Uganda is 25-30% (Legros et al., 1999). 
 
 
1.11.2 Pentamidine 
 
Pentamidine isothionate is an aromatic diamidine (Figure 1.4) and was first introduced 
in 1937 under the trade name Pentacarinate. It is now manufactured under the name of 
Lomidine
® (Pepin and Milord, 1994). It does not cross the blood-brain barrier and is the 
standard treatment of early T. b. gambiense infection or in patients with CNS 
involvement only to clear blood of trypanosomes prior to treatment with melarsoprol 
(Docampo and Moreno, 2003). The mode of action of Pentamidine has not been 
established, although it has been shown to bind to nucleic acids and a network of 
circular DNA molecules present in the kinetoplast leading to disruption of the structure 
of the kinetoplast. However, Wang (1995) has reported that this mechanism of action 
would be insufficient to kill the parasites and therefore, another undiscovered 
mechanism of action exists.  Chapter 1. Introduction 
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Treatment using Pentamidine involves 7-10 doses at 4mg/kg body weight (b.w.) by 
intra-muscular (i.m) injection either daily or every other day (see Table 1.2) (Legros et 
al., 1999). Local reactions can occur at the site of injection with pain and the formation 
of sterile gluteal abscesses. Other side effects include pruritus, rash, tachycardia, nausea 
and vomiting (Docampo and Moreno, 2003). Nephrotoxicity, hepatotoxicity and 
pancreatic toxicity occur in some patients (Fairlamb, 2003; Pepin and Milord, 1994) and 
diabetes mellitus can develop after therapy (Burchmore et al., 2002; Nok, 2003). Some 
resistance has been reported in the laboratory with T. b. brucei. Drug-resistant strains 
were shown to have a diminished ability to import the drug, which is believed to be the 
primary cause of Pentamidine resistance (Wang, 1995). Fortunately, widespread 
resistance has not yet emerged in the field (Docampo and Moreno, 2003; Pepin and 
Milord, 1994). 
 
 
 
Figure 1.4 Structures of drugs used to treat human African trypanosomiasis: a) Suramin, b) 
Melarsoprol, c) Pentamidine and d) Eflornithine (Fairlamb, 2003) 
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1.11.3 Suramin 
 
 
Suramin is a polysulphonated naphthylamine polyanionic compound (Figure 1.4). Its 
original trade name was Bayer 205 and it was first used for the treatment for HAT in 
1922 (Wang, 1995). It was developed because its two close analogues trypan blue and 
trypan red were shown to be effective anti-trypanosomatids in the early twentieth 
century (Docampo and Moreno, 2003). The main mechanism of action of suramin is 
still unclear but has been shown to inhibit many enzymes such as dihydrofolate 
reductase, thymidine kinase and glycolytic enzymes (Wang, 1995). It is thought to 
inhibit multiple targets which could explain why there has been no significant clinical 
resistance to Suramin in its 80 years of use (Fairlamb, 2003). Its selectivity for 
trypanosomes is due to their ability to readily take up the drug. Suramin is slowly 
excreted because it binds to many serum proteins and its half life of around 90 days is 
one of the longest ever documented for drugs given to humans (Fairlamb, 2003; Pepin 
and Milord, 1994). 
 
The present protocol for treatment using Suramin is administration of 5mg/kg b.w. at 
day 1, 10mg/kg b.w. at day 3 and 20mg/kg b.w. at days 5, 11, 23, and 30. This is 
administered by slow i.v. injection (see Table 1.2) (Docampo and Moreno, 2003). 
Subcutaneous or intramuscular injections are not recommended because Suramin causes 
local inflammation and necrosis (Pepin and Milord, 1994). Suramin is only used during 
early stages of the disease because it is highly ionic and does not penetrate well into the 
CNS (~1% of serum levels) (Fairlamb, 2003). It can be used for the treatment of early 
stage T. b. rhodesiense and T. b. gambiense, although it is generally used only for T. b. 
rhodesiense most likely due to treatment failures, the duration and cost of treatment and 
the need for it to be administered by i.v. injection (Pepin and Milord, 1994). The most Chapter 1. Introduction 
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common toxic effect of Suramin treatment is renal toxicity, although it is usually mild 
(Docampo and Moreno, 2003).  Collapse and shock also occurs in some treated patients 
(Fairlamb, 2003). Delayed reactions include optic atrophy, blindness, exfoliative 
dermatitis, haemolytic anaemia, jaundice, adrenal insufficiency and severe diarrhoea in 
some patients (see Table 1.2) (Fairlamb, 2003; Pepin and Milord, 1994).  
 
 
Table 1.2   Drug programmes currently in use against Human African Trypanosomiasis. 
 
Drug         Eflornithine          Melarsoprol              Pentamidine           Suramin    
 
Chemistry         difluoromethyl-                   arsenical                                  diamidine                               sulphated 
                           ornithine                                                                                                                             naphthylamine                                                   
 
Application       intra-venous                         intra-venous                            intra-muscular                       intra-venous                   
 
Indications        early- late stage                   early - late stage                      early stage                              early stage 
                  T. b. gambiense                   T. b. gambiense                      T. b. gambiense                       T .b .gambiense  
                                                                       T. b. rhodesiense                                                                    T. b. rhodesiense           
 
Dosage               4 × 100mg/kg b.w/day        2.2mg/kg b.w/day                   4mg/kg b.w/day                     5mg/kg b.w Day 1 
                           every 6hr  × 7-14days         × 10 days                                 × 7 days                                 10mg/kg b.w Day 3 
                                                                                                                                                                      20mg/kg b.w 5,11,23,30                                    
                                                                                                                                                  
Mode of             Inhibits biosynthesis of       unknown                                 Reduces biosynthesis             Inhibits enzymes eg  
Action                polyamines                                                                          polyamines                             RNA polymerase 
 
Side Effects       convulsions, diarrhoea        reactive encephalopathy         pruritis, rash, tachycardia       nephrotoxicity, blindness                                  
                           anaemia, leucopenia            polyneuropathy,                     hepato and nephrotoxicity,     exfoliative dermatitis 
                           thrombocytopenia               exfoliative dermatitis,             pancreatic toxicity                  haemolytic anaemia 
                                                                        joint pain, fever, malaise       nausea, vomiting                     diarrhoea, jaundice 
                                                                       g.i. disturbances, headache,                                                    collapse, shock,  
                                                                       renal damage, hypertension                                                     
 
 
1.11.4 Melarsoprol 
 
 
Melarsoprol is a trivalent organic melaminophenyl arsenical (Figure 1.4) that was first 
synthesised over 50 years ago by Freidheim (Docampo and Moreno, 2003). Its trade Chapter 1. Introduction 
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name is Arsobal and it is used to treat late stages of T. b. gambiense and T. b. 
rhodesiense infection because it is able to cross the blood-brain barrier (Burchmore et 
al., 2002; Docampo and Moreno, 2003). Melarsoprol is poorly soluble in water, alcohol 
or ether and is administered intra-venously dissolved in propylene glycol, a solvent that 
is highly irritant to tissues (Fairlamb, 2003; Nok, 2003). Melarsoprol is very effective 
but the exact mechanism by which this is achieved remains elusive. The most likely 
mode of action is that it inhibits glycolytic enzymes leading to a blockage of glycolysis 
and cell lysis (Wang, 1995). Treatment of trypanosomiasis using Melarsoprol consists 
of 3-4 series of  3-4 daily injections of 3.6mg/kg b.w. separated by rest periods of 7-10 
days (Docampo and Moreno, 2003) (see Table 1.2).  
 
Melarsoprol is extremely toxic and often patients relapse after treatment (Burri and 
Brun, 2003). The worst side effect is a reactive encephalopathy, which occurs in 5-10% 
of patients and results in the death of 10-50% of those affected (Docampo and Moreno, 
2003; Pepin et al., 1995). Other side effects include polyneuropathy (10%), exfoliative 
dermatitis (1%), abdominal and chest pain, fever, headache, malaise, joint pain, 
gastrointestinal disturbances, renal damage and hypertension (see Table 1.2) (Docampo 
and Moreno, 2003; Pepin and Milord, 1994). Administration of the drug causes pain 
and thrombophlebitis at the site of injection is common (Nok, 2003). The relapse rate in 
patients treated with Melarsoprol is 3-10% however, in epidemic areas of T. b. 
gambiense, this rate has increased dramatically in recent years to 30% in northwestern 
Uganda, 21% in southern Sudan, 25% in northern Angola (Burri and Brun, 2003). 
Recent studies have shown that men have a higher risk of treatment failure than women, 
although the cause of this apparent difference is unknown (Pepin et al., 2002). 
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A new treatment schedule was proposed recently based on pharmacokinetic studies and 
computer modelling, which decreases the time required for treatment and the amount of 
drug administered to 10 daily doses of 2.2mg per kg body weight (Blum and Burri, 
2002). This new treatment schedule was tested in an open randomised clinical trial 
involving 500 patients in Angola (Burri et al., 2000). A follow-up was conducted two 
years after this trial to determine the relapse rate compared with those patients treated 
using the standard Melarsoprol schedule (Schmid et al., 2004). The findings of this 
study showed that, although cure rates and relapse rates were the same in both groups, 
the amount and cost of drug was reduced by approximately 30%. In addition, the 
number of patients requiring hospitalization was reduced by approximately 50% and the 
total amount of Melarsoprol given is reduced which will decrease toxicity without 
reducing efficacy (Schmid et al., 2004). The shorter protocol has recently been 
recommended by the International Scientific Council for Trypanosomiasis Research and 
Control for the treatment of late-stage HAT caused by T. b. gambiense (Schmid et al., 
2005). 
 
 
1.11.5 Eflornithine 
 
 
Eflornithine is the only new drug registered for treatment of HAT in the last fifty years 
(Burri and Brun, 2003). It is a difluoromethyl ornithine (see Figure 1.4) and was 
registered for use in 1990 under the trade name of Ornidyl (Docampo and Moreno, 
2003). Eflornithine is effective against T. b. gambiense infection even in the late stages 
of the disease (Burchmore et al., 2002; Milord et al., 1992). It inhibits trypanosomal 
ornithine decarboxylase (ODC), which is the key enzyme in the pathway leading to the 
biosynthesis of polyamines essential for cell proliferation. Following treatment the 
trypanosomes become non-dividing stumpy forms that are vulnerable to the host Chapter 1. Introduction 
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immune system because they cannot alter their variant surface glycoproteins (Wang, 
1995). Eflornithine is therefore trypanostatic rather than trypanocidal (Pepin and 
Milord, 1994). T. b. rhodesiense is resistant to Eflornithine because of its higher ODC 
turnover (Burri and Brun, 2003). 
 
Large doses of Eflornithine are required in order to be effective against HAT. The 
treatment protocol is 400mg per kg body weight per day in 4 daily intra-venous 
infusions for 7-14 days (Burchmore et al., 2002) (see Table 1.2). This costs 
approximately U.S.$350 per patient for the drug alone. Due to the high cost, 
Elfornithine is mainly used as a second line treatment after Melarsoprol (Burri and 
Brun, 2003). Attempts to reduce the treatment course of Eflornithine have not been 
successful and it has been shown that a 7-day course of Eflornithine treatment is less 
efficacious compared to a 14-day course with new cases, however, a 7-day course is 
recommended where infection has relapsed (Khonde et al., 1997; Pepin et al., 2000). 
Some adverse reactions accompany the use of Eflornithine, which are completely 
reversible once treatment ceases (Burri and Brun, 2003). These side effects include 
convulsions and other neurological effects (7%), gastrointestinal disturbance such as 
nausea, vomiting and diarrhoea (10-39%) and bone marrow toxicity leading to anaemia, 
leucopoenia and thrombocytopenia (25-50%) (Burri and Brun, 2003; Pepin and Milord, 
1994). 
 
Eflornithine and the trivalent arsenicals (Melarsoprol) have been shown to act 
synergistically in animal models and promising results from preliminary trials of 
combination therapy for melarsoprol-resistant T. b. gambiense infection suggests that 
this approach should be explored further (Mpia and Pepin, 2002). Chapter 1. Introduction 
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1.11.6 Treatment for Nagana 
 
 
Drug resistance is a major problem in the chemotherapy of trypanosomiasis in domestic 
ruminants in Africa. There are currently three drugs available for the treatment of 
animal trypanosomiasis caused by T. congolense, T. vivax and T. b. brucei. 
Isometamidium has both prophylactic and curative effects and can be administered 
either subcutaneously or intra-muscularly (Geerts et al., 1999). Homidium also has both 
prophylactic and curative effects whilst diminizene has only curative effects. The supply 
of these drugs was once strictly controlled by Government Veterinary Departments, 
however, the recent privatisation of veterinary services and a general deregulation of 
pharmaceutical markets have resulted in them becoming freely available to farmers, 
which has increased the risk of their misuse. Trypanocides are often the first drugs 
administered to cattle developing any symptom of disease because at U.S.$1 per 
treatment it is most affordable for farmers (Geerts et al., 2001). As a result they are 
frequently used without an accurate diagnosis and under-dosage commonly occurs 
(Holmes, 1997). Moreover, it has been estimated from studies in Zambia that half the 
animals treated with trypanocides are not infected with trypanosomes (Geerts et al., 
2001). 
 
 
1.11.7  Future Prospects for Chemotherapy 
 
 
Current treatments for trypanosomiasis are unsatisfactory due to severe adverse 
reactions, high treatment cost and increasing treatment failures. New cost-effective and 
easy to administer drugs are urgently needed. The immediate focus is on the 
development of new treatment programmes using existing drugs such as Eflornithine 
more efficiently (Fairlamb, 2003). Chapter 1. Introduction 
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Combination therapy could increase the efficacy of treatment if there is a synergistic 
effect, which may increase cure rates, lower dose rates or shorten duration of treatment 
(Keiser et al., 2001). Several combinations of drugs have been tested clinically 
including Suramin and Pentamidine (Pepin and Khonde, 1996), Eflornithine and 
Melarsoprol (Mpia and Pepin, 2002) and Eflornithine and Suramin (Clerinx et al., 
1998). Nifurtimox, a 5-nitrofuran is used to treat trypanosomiasis in South America 
(Pepin and Milord, 1994) and has been studied in combination with Melarsoprol and 
Eflornithine with promising results (Van Nieuwenhove, 1992). However, these studies 
were performed on a small-scale and none of the protocols have been tested in full 
clinical trials. 
 
A potential new trypanocidal drug is currently undergoing clinical trials. DB289 [2,5-
bis(4-amidinophenyl)furan-bis-O-methylamidoxime] is a new oral drug for the 
treatment of first stage HAT and has progressed through phase I trials and is currently 
undergoing phase II clinical trials (http://www.sti.ch/scih/africa1.htm). It is a derivative 
of the diamidine DB75 [2,5-bis(4-amidinophenyl)furan] which was previously tested in 
primates infected with T. b. rhodesiense in the 1980’s. DB75 failed to show any 
therapeutic advantage over Pentamidine and was not developed further (Fairlamb, 
2003). DB289 has an advantage over Pentamidine in the treatment of first stage 
infection because it can be administered orally. However, it takes at least six years for a 
drug to be approved for use from Phase I (Keiser et al., 2001) and so it seems unlikely 
that DB289 will be registered this decade. 
 
Compounds extracted from medicinal plants have also been evaluated as possible 
treatment for HAT. Proanthocyadinin is a known antioxidant and can be extracted from 
Kola nuts from Kola acuminata trees, which are indigenous to West and Central Africa. Chapter 1. Introduction 
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This compound was shown to be more effective against T. brucei in vitro than 
pentamidine. However, it only exhibited trypanostatic effects in vivo and more research 
is required to elucidate the target and mode of action in trypanosomes and also to 
improve its physico-chemical properties (Kubata et al., 2005). 
 
In the long term, since sequencing of the T. brucei genome is complete (Berriman, et 
al., 2005), the future question is how best to exploit new information about 
trypanosomes because a number of new potential targets have been identified. These 
new targets include trypanothione (Schmidt and Krauth-Siegel, 2002), proteasome 
(Nkemngu et al., 2002) polyamine biosynthetic enzymes (Heby et al., 2003), enzyme 
transporters involved in galactose metabolism (Roper et al., 2002), (Ѕ)-adenosyl-L-
methionine:Δ
24-sterol methyltransferase (24-SMT) (Lorente et al., 2004) and tubulin 
(Ochola et al., 2002). Studies using compounds that are known to bind to some of these 
targets have begun, for example, trileucine methyl vinyl sulfone, a proteasome inhibitor 
and azasterols, inhibitors of 24-SMT, have shown in vitro activity against T. brucei with 
promising results (Lorente et al., 2004; Steverding et al., 2005). 
 
 
1.12  Tubulin as a Novel Drug Target  
 
 
1.12.1  Potential of Tubulin as a Drug Target 
 
 
Tubulin is a promising target for the development of new trypanocidal drugs because 
they are highly conserved within the Trypanosomatidae family but differ from that of 
mammals. Disruption of the tubulin-microtubule equilibrium can lead to a cascade of 
direct and indirect biochemical and physiological changes resulting in the loss of Chapter 1. Introduction 
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cellular homeostasis. If this state in the cell is maintained, the result is fatal (Lacey, 
1988). 
 
 
1.12.2 Benzimidazoles 
 
Benzimidazoles have been widely used since 1961 as anthelmintics in veterinary and 
human medicine (Kohler, 2001) and as antifungal agents in agriculture (Katiyar et al., 
1994). They are thought to bind to β-tubulin (Hollomon et al., 1998; Lubega et al., 
1993; Nogales, 2000) which interferes with the polymerization of tubulin and 
subsequently inhibit mitosis (Martin, 1997). Benzimidazoles exhibit selective toxicity 
binding more strongly and irreversibly with helminth tubulin in comparison to 
mammalian tubulin (Lacey, 1988). Benzimidazoles have demonstrated activity in vitro 
against Giardia duodenalis (Meloni et al., 1990; Morgan et al., 1993), Plasmodium 
falciparum (Dieckmann-Schuppert and Franklin, 1989), Trichomonas vaginalis (Katiyar 
et al., 1994) and T. b. brucei (Ochola et al., 2002). 
 
Little or no activity has been observed against Leishmania infantum (Armson et al., 
1999a),  L. major, Entamoeba histolytica, Acanthamoeba polyphaga (Katiyar et al., 
1994) and Fasciola hepatica (Robinson et al., 2001). Most recently, the binding kinetics 
of benzimidazoles have been studied on β-tubulin from G. duodenalis, E. intestinalis, C. 
parvum (Macdonald et al., 2004) and P. falciparum (Low, 2005), further supporting the 
hypothesis that benzimidazoles bind to β-tubulin selectively.  
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1.12.3 Dinitroanilines 
 
Dinitroanilines are tubulin-binding agents that were originally recognised for their 
herbicidal properties and are used commercially for the elimination of grasses and 
broadleaf weeds (Chan and Fong, 1994). They act by disrupting tubulin polymerization, 
inhibiting mitosis and causing a loss of orientation of cell wall microfibrils so that 
rectangular shaped cells become round (Chan et al., 1991; Chan et al., 1993). 
 
The anti-protozoal activity of dinitroanilines has been demonstrated against a number of 
protozoan parasites. Trifluralin has shown activity against C. parvum (Armson et al., 
1999b),  Leishmania sp.., T. brucei (Chan and Fong, 1990; Chan et al., 1993) and 
Plasmodium sp. (Dow et al., 2002) (Kaidoh et al., 1995). Oryzalin, ethalfluralin and 
trifluralin have shown activity against Toxoplasma gondii in vitro with low toxicity to 
mammalian host cells (Morrissette et al., 2004; Stokkermans et al., 1996). In addition, 
anti-protozoal activity has been demonstrated in vivo by trifluralin and oryzalin against 
C. parvum (Armson et al., 1999b), Leishmania sp. (Chan et al., 1993). However, not all 
protozoan parasites are sensitive to dinitroanilines. Entamoeba histolytica was not 
sensitive to trifluralin even at high concentrations and, whilst oryzalin arrested mitosis, 
the effects were reversible on removal of the drug (Makioka et al., 2000). 
 
The putative target of dinitroanilines is α-tubulin. Recent studies showed that the 
dinitroaniline oryzalin was binding consistently and with great affinity to α-tubulin 
(Morrissette et al., 2004) (Stokkermans et al., 1996). Moreover, oryzalin resistant 
Toxoplasma possessed a point mutation in the single α-tubulin gene. In the 
dinitroaniline resistant weed Eleusine indica, a point mutation in the α-tubulin gene was 
also found (Anthony and Hussey, 1999). Interestingly, the activity of dinitroanilines is Chapter 1. Introduction 
  40
restricted to plants and protozoa. These compounds are ineffective against mammalian 
or fungal microtubules (Bajer and Mole-Bajer, 1986; Chan and Fong, 1990; Dow et al., 
2002; Hess and Bayer, 1977; Hugdahl and Morejohn, 1993). 
 
 
1.13  The Present Study 
 
 
The hypothesis being investigated in this project is that the structural protein, tubulin, is 
a potential target for anti-trypanosomatid drug discovery and vaccine development. 
Recombinant α- and β- tubulin proteins from T. brucei will be expressed, drug binding 
kinetics will be studied and potential anti-trypanosomatid drugs evaluated based on 
strength and affinity of binding to tubulin. In addition to this, recombinant trypanosomal 
tubulin will be used to explore the possibility of its ability to provide protective 
immunity in an animal model. 
 
A safe and effective anti-trypanosomatal agent has yet to be found. The most promising 
class of compounds being explored recently are the dinitroanilines, particularly 
trifluralins. Further evaluation of these compounds requires pure tubulin for use in drug-
binding assays to determine the binding characteristics of trifluralins and to enable the 
development of more active analogues. In addition, drug-treated bloodstream forms of 
T. brucei will be studied using electron microscopy and immunofluorescence in order to 
determine what ultrastructural changes these compounds induce as a result of tubulin 
binding.  
 
Currently there are no available vaccines against African trypanosomiasis and prospects 
for the development of a vaccine are considered to be very poor due to the fact that Chapter 1. Introduction 
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trypanosomes regularly change their vsg surface coat. Alternatively, invariant 
trypanosome components are currently being explored as potential vaccines and this 
study will focus on whether tubulin can provide a target for vaccine development. Mice 
will be immunized with recombinant α- and β-tubulin, challenged with T. brucei and 
monitored for trypanosome infection and survival. It will also be determined whether a 
difference exists between α-tubulin and β-tubulin in providing immuno-protection. 
With inadequate treatment currently available against African trypanosomiasis, the 
discovery of a vaccine would be ideal as a safe and cost-effective way of controlling 
African trypanosomiasis.  
.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter 2 
 
Expression and Purification of Recombinant  
Tubulin From Trypanosoma brucei                          
Using Fusion Partners. 
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2.1   Introduction 
 
Bacterial expression systems provide economic and logistic advantages in producing 
large amounts of recombinant protein. However, there are also many problems 
associated with expressing protein in bacteria because proteins tend to aggregate or 
accumulate in inclusion bodies when produced to high levels, become degraded by host 
proteases (Wilkinson and Harrison, 1991) and purifying the protein of interest can be 
difficult (Davis et al., 1999). This leads to problems refolding the recombinant protein 
in vitro with an increased possibility of mis-folding or incomplete folding intermediates 
being produced. Despite improvements in the procedures for refolding proteins from 
inclusion bodies (De Bernardez Clark, 1998; Lilie et al., 1998) the recovery yield of 
biologically active protein is frequently unsatisfactory (Lilie et al., 1998). To avoid this, 
it is desirable to maximise the expression of the protein in completely soluble form. 
 
Over the past decade, much progress has been made in the understanding of protein 
structure and protein folding (Hockney, 1994). This has lead to the development of a 
strategy to aid in the solubilization of recombinant proteins in E. coli, which involves 
fusing the gene of interest to a second “carrier” gene to produce a fusion protein 
(Sassenfeld, 1990). An appropriate gene fusion can enhance solubility, decrease 
proteolysis of target protein and provide an affinity purification tag (Georgiou and 
Valax, 1996; LaVallie and McCoy, 1995; MacDonald et al., 2003; Nilsson et al., 1997). 
The most common carrier proteins for fusion protein expression in E. coli are maltose-
binding protein (MBP) (New England Biolabs, Beverly, MA) (di Guan et al., 1988; 
Hennig and Schafer, 1998; Riggs, 2000; Sachdev and Chirgwin, 1998; Sachdev and 
Chirgwin, 2000) glutathione S-transferase (GST) (Amersham Biosciences) (Smith et 
al., 1998) thioredoxin (TrxA) (Invitrogen) (LaVallie et al., 1993; Sachdev and  
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Chirgwin, 1998; Yasukawa et al., 1995) and polyhistidine (Novagen; Qiagen). Other 
systems include protein A and its derivative protein Z (Pharmacia Biotech), FLAG 
peptide (Kodak) and PinPoint (Promega) (Nilsson et al., 1997). 
 
MBP is commercially available as a fusion protein kit (New England Biolabs, Beverly, 
MA) that utilises the pMAL plasmid vector (Figure 2.1) containing the malE gene 
encoding maltose-binding protein. The cloned gene of interest is inserted downstream 
from the malE gene resulting in the expression of an MBP fusion protein (di Guan et 
al., 1988; Maina et al., 1988). MBP, a protein found in E. coli, is exported into the 
periplasmic space where it binds specifically to maltose or maltodextrins for subsequent 
transport across the cytoplasmic membrane  (Duplay et al., 1984). A high level 
expression of the cloned gene occurs by use of a strong chemically inducible “tac” 
promoter (Amann and Brosius, 1985) and malE translation initiation signals (Duplay et 
al., 1984). Once the fusion protein is expressed in E. coli it can be purified using 
affinity chromatography using a column of a cross-linked amylose matrix that binds 
MBP. The MBP fusion protein is subsequently eluted using MBP’s affinity for maltose 
(Kellermann and Ferenci, 1982). The pMAL vector also contains the sequence coding 
for the recognition site of the specific protease Factor Xa (Nagai and Thogersen, 1984), 
which is located 5´ to the polylinker insertion sites. This allows MBP to be cleaved 
from the protein of interest after purification. Factor Xa cleaves after its four amino acid 
recognition sequence so that few or no vector-derived residues are attached to the 
protein of interest, depending on the site used for cloning. 
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Figure 2.1 Map of the maltose-binding protein fusion vector (pMAL™-2) showing 
the reading frame and main features. Arrows indicate the direction of transcription. 
Unique restriction sites are indicated. 
 
 
 
 
Figure 2.2 Map of glutathione S-transferase fusion vector (pGEX-6P-1) showing 
the reading frame and main features. Arrows indicate the direction of transcription. 
Unique restriction sites are indicated.  
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GST is also commercially available as a fusion protein kit (Amersham Biosciences, 
Buckinghamshire, England) and uses the pGEX plasmid vector (Figure 2.2) containing 
the gene encoding GST. The cloned gene of interest is inserted downstream from the 
GST gene resulting in the expression of a GST fusion protein. This vector also contains 
the strong “tac” promoter for chemically inducible high-level expression in E. coli. GST 
is a 26kDa protein naturally occurring in the parasitic helminth Schistosoma japonicum 
(Smith et al., 1986). Using the pGEX vector GST can be expressed in E. coli with full 
enzymatic activity (Smith and Johnson, 1988) and a high degree of solubility (Smith et 
al., 1988). Purification is carried out under non-denaturing conditions using affinity 
chromatography by immobilizing GST to cofactor glutathione and then eluting with 
reduced glutathione (Simons and Vander Jagt, 1981). The pGEX vector also contains 
the sequence coding for the recognition site of the specific proteases thrombin and 
Factor Xa to allow the cleavage of the GST fusion partner (Smith and Johnson, 1988). 
 
Trypanosomal tubulin proteins are predominantly cytoskeletal proteins, comprising of 
up to 10% of the total cellular protein content (Chan and Fong, 1994). Each molecule of 
tubulin is a heterodimer consisting of α- and β- tubulin subunits. The αβ heterodimer 
polymerise to form microtubules (Lacey, 1988). Alpha-tubulin is composed of 451 
amino acids and has a M.W of 49.7kDa and β-tubulin is composed of 442 amino acids 
and has a M.W. of 49.8kDa (Kimmel et al., 1985). They are both acidic proteins with 
theoretical pI of 4.93 for α-tubulin and 4.72 for β-tubulin. The acidity is due to the high 
number of acidic residues, especially glutamic acid in the carboxy-terminal of the 
monomers (Lacey, 1988).   
 
Wu and Yarbrough (1987) expressed the tubulin genes from T. brucei in E. coli but they 
were unable to solubilize them from the inclusion bodies. Both tubulin subtypes from  
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the parasitic protozoa Giardia duodenalis, Cryptosporidium parvum, Encephalitozoon 
intestinalis  (MacDonald et al., 2001; MacDonald et al., 2003) and Plasmodium 
falciparum (Low, 2005) have been expressed in E. coli in soluble form using various 
expression systems.  
 
Tubulins are highly conserved within the Trypanosomatidae but are different from that 
of mammalian hosts (Lacey, 1988). Past work suggests that tubulin from kinetoplastid 
parasites could potentially be an efficient drug target (Armson et al., 1999b; Ochola et 
al., 2002). Production of pure tubulin for use in drug-binding assays will provide 
significant insights into the binding characteristics of the trifluralin analogues and allow 
a faster and more efficient screening of the various analogues of trifluralin.  
 
 
The aims of this study were: 
 
1.  To produce soluble recombinant α-tubulin and β-tubulin protein from 
Trypanosoma brucei. 
2.  To purify the recombinant α- and β-tubulin with minimal losses whilst 
maintaining the structural integrity of the proteins. 
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2.2   Materials and Methods 
 
 
2.2.1   Trypanosomes 
 
 
T. b. rhodesiense (ATCC, 30027) were purified from the blood of highly parasitaemic 
rats by overlaying 1ml of infected blood onto 5ml of Percoll at a specific gravity of 
1.075 (Amersham Biosciences, Buckinghamshire, England) and centrifuging at 1,500 × 
g for 10min at 4
oC. The layer above the Percoll containing trypanosomes was removed 
and washed once with 5ml of PBS (20mM Na2PO4, 150mM NaCl, pH 7.2) and 
centrifuged again at 1,500 × g for 2min to collect the pellet. The pellet of trypanosomes 
was resuspended in 1ml of PBS and stored at –80
oC until required for use. 
 
 
2.2.2  DNA extraction and PCR amplification of trypanosomal tubulin genes 
 
 
Whole genomic DNA from T. b. rhodesiense was extracted using the Ultra Clean Gel 
Spin™ DNA purification kit (Mo Bio, Solana Beach, CA) and Prep-a-gene matrix (Bio-
Rad, Hercules, CA) according to the manufacturer’s instructions. Forward and reverse 
primers for α-tubulin and β-tubulin were designed using sequence data from Kimmel, et 
al. (1985) (Table 2.1). The primers were designed to introduce unique restriction sites 
into the tubulin genes for unidirectional ligation into their respective vectors: namely, 5’ 
BamHI and 3’ XbaI for α-tubulin to be cloned into the pMAL-c2x vector (New England 
Biolabs, Beverly, MA) and 5’BamHI and 3’XhoI for β-tubulin to be cloned into the 
pGEX-6p1 vector (Amersham Biosciences, Buckinghamshire, England). No start 
codons were included to ensure the tubulin sequence was translated as part of the fusion 
protein.   
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The likelihood of a PCR product being generated with these primers was assessed using 
the PCR Amplify programme version 1.2 (Bill Engels, Madison, U.S.A.) The 
theoretical specificity of the primers was determined using BLAST against Genbank.  
 
 
Table 2.1. Primer sequences used to amplify T.b.rhodesiense tubulin genes. 
 
            
             Gene and Primer                      Primer Sequence 
 
 
      α-tubulin     forward primer          5’-GATTAAGGATCCCGTGAGGCTATC-3’ 
 
                           reverse primer           5’-CGGTCTAGACACTTTCTAGTACTC-3’ 
 
 
      β-tubulin     forward primer          5’-GATTTAGGATCCCGCGAAATCGTCTGC-3’ 
 
                           reverse primer           5’-GGCTTACTCGAGCTAGTATTGCTCCTC-3’ 
 
 
 
PCR amplification of α- and β-tubulin genes were prepared as follows: 
   10μl GeneAmp 10× PCR Buffer  
 4U AmpliTaq DNA Polymerase 
   200μM each dNTP (all from Applied Biosciences, Foster City, CA) 
   25pM each primer (Gibco BRL, Rockville, U.S.A) 
 5ng genomic DNA  
PCR grade ultra pure water to a final volume of 100μl.  
 
Amplifications were performed on a Perkin-Elmer PE 2400 Thermal Cycler (Foster 
City, USA) under the following conditions: 95
oC for 5min; 30 cycles of 95
oC for 1min, 
61
oC for 45sec, 72
oC for 1min, 30sec and a final 72
oC elongation step for 7min for α-
tubulin. The same PCR conditions were followed for β-tubulin with the exception of the 
annealing temperature, which was changed to 55
oC.   
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2.2.3  Preparation of plasmid and tubulin genes for cloning  
 
 
PCR products were cleaned using the Wizard Prep Kit (Promega, Madison, WA) 
following the manufacturer’s instructions and then a restriction endonuclease digest was 
performed to prepare the PCR products for cloning. These were performed in two steps. 
For the first step, the following reaction was prepared; 0.5μg of α-tubulin DNA, 10 
units of XbaI restriction endonuclease, 2.0μl 10× XbaI buffer (Promega, Madison, WA) 
were added to a final volume of 20μl ddH2O. This was incubated for 18hr in a 37
oC 
water bath. The restriction endonuclease was then inactivated in an 85
oC water bath for 
15min before the second part of the reaction was conducted. To the initial reaction 10 
units of BamHI restriction endonuclease, 2.0μl of 10×  BamHI buffer (Promega, 
Madison, WA) were added to a final 25μl volume of ddH2O and incubated for 5hr at 
37
oC. The same procedures were performed on the β-tubulin insert replacing XbaI with 
XhoI (Promega, Madison, WA). 
 
To prepare the pMAL and pGEX plasmid vectors for cloning a restriction endonuclease 
digestion was performed using the method used for their respective inserts on the same 
amount of DNA. The cleaved vectors were then treated with 1U of alkaline phosphatase 
(Promega, Madison, WA) for 1hr at 37
oC to remove the phosphate ends and prevent the 
ends re-ligating.  
 
 
2.2.4 Plasmid  construction  and  sequencing of tubulin genes 
 
 
Once digestion of the α-tubulin gene and pMAL vector were complete, a ligation 
reaction mixture was prepared as follows: 90fmol of α-tubulin, 30fmol of pMAL, 2U of 
T4 DNA Ligase (Gibco BRL, Rockville U.S.A.), 2.0μl 10×T4 Ligase Buffer (Gibco  
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BRL, Rockville U.S.A.) in a total volume of 20μl with ddH2O. This reaction mixture 
was incubated at 16
oC for 24hr. The same protocol was followed for β-tubulin 
substituting α-tubulin for β-tubulin and the pMAL vector for the pGEX vector. 
 
The tubulin constructs were transformed into DH5α  E. coli competent cells by a 
standard heat shock procedure, plated onto Luria-Bertani (LB) plates containing 50 
μg/ml ampicillin and incubated overnight at 37
oC. Single colonies were cultured in 2ml 
of LB broth containing 50μg/ml ampicillin for 18hr with shaking at 37
oC. The construct 
DNA was isolated from the culture using standard extraction procedures and then 
sequenced in both directions to ensure complete integrity using sequencing primers 
designed by the manufacturers for the pMAL and the pGEX vectors respectively (Table 
2.2) and the ABI PRISM dye terminator cycle sequencing kit (Perkin-Elmer, Foster 
City, CA) according to the manufacturer’s recommended method. 
 
 
Table 2.2. Primer sequences used to amplify T. b. rhodesiense tubulin gene constructs. 
 
     Vector and Primer                           Primer Sequence 
 
 
     pMAL-c2x    forward primer         5’-CGATGAAGCCCTGAAAGACGCGCAGAC-3’ 
 
                            reverse primer          5’-TGGGTAACGCCAGGGTTTTCCCAGTCA-3’ 
 
 
     pGEX-6p1    forward primer         5’-GGGCTGGCAAGCCACGTTTGGTG-3’ 
 
                            reverse primer          5’-CCGGGAGCTGCATGTGTCAGAGG-3’ 
 
 
 
 
 
2.2.5 Transformation  of  E. coli and induction of gene expression 
 
 
Once the trypanosomal tubulin constructs were confirmed (pMAL-α-tubulin and 
pGEX-β-tubulin) they were transformed into BL21(DE3)pLysS protein expressing cells  
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(Invitrogen) and single colonies were cultured in 2ml of LB broth containing 50μg/ml 
of ampicillin and 35μg/ml of  chloramphenicol and incubated at 37
oC  for 18hr with 
shaking.  
 
To determine the optimal protein expression conditions, the volume of the E. coli 
cultures were increased to 50ml and grown at 25
oC, 30
oC or 37
oC. The mid-log phase 
was determined using optical density (OD) measurements (wavelength 600nm). Once 
the OD600 was between 0.4 and 0.6 protein expression was induced by adding 0.1mM, 
0.5mM or 1mM total concentration of isopropyl-beta-D-thiogalactopyranoside (IPTG). 
Samples of 1ml were removed hourly after induction to determine the optimal 
incubation time, incubation temperature and IPTG concentration that resulted in the 
highest yield of fusion protein. The concentration of fusion protein in uninduced 
bacterial cultures was also determined to provide the basal bacterial protein expression 
levels. The unligated plasmids pMAL-c2x and pGEX-6p1 were also transformed into 
BL21(DE3)pLysS cells and treated as described above to provide samples of the fusion 
partner only.  
 
 
2.2.6  Fusion protein analysis 
 
 
The 1ml samples collected during expression were centrifuged at 14,000 × g  for 1min 
at 4
oC and the pellet resuspended in 100μl of protein sample buffer (10% SDS, 0.5M 
Tris-HCl pH 6.8, 50% glycerol, 0.01% bromophenol blue, 0.1ml 2β-mercaptoethanol 
made up to 10ml with ddH2O). The cells were then lysed by freeze-thawing 3 times and 
sonicated using a Misonix ultrasonic sonicator (Daintree Scientific, Tasmania) for 15sec 
with 10sec intervals for a total of 10 cycles. The crude lysate was then centrifuged at  
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14,000  ×  g f o r  1 m i n  a t  4
oC to separate soluble (supernatant) and insoluble (pellet) 
fractions. Proteins were visualised using SDS-PAGE (Laemmli, 1970) to determine the 
optimal temperature, time and IPTG concentration for highest yield of soluble fusion 
protein. Samples of 20μl were loaded onto 10% Tris-glycine polyacrylamide pre-cast 
gels (Gradipore, Frenchs Forest, Australia) and electrophoresed at 90V (constant 
voltage) for 120min in electrophoresis buffer (containing 3.75% Tris, 1.25% SDS and 
18% glycine in ddH2O) in a Bio-Rad Mini-Protean apparatus (Hercules, U.S.A.). The 
gels were stained in Coomassie staining solution (50% ddH2O, 40% methanol, 10% 
acetic acid and 0.1% Coomassie Brilliant Blue R-250) for 18hr. The gels were then 
destained for 24hr in a solution of 50% ddH2O, 40% methanol and 10% acetic acid.   
 
Western and Dot Blots were performed using polyvinylidene diflouride (PVDF) 
membranes (MSI, Westboro, MA) according to the method of Towbin et al. (1979). For 
the putative MBP-α-tubulin fusion protein the presence of the MBP carrier protein was 
determined using a monoclonal anti-MBP antibody (Sigma, St Louis, MO) and 
confirmation that the fusion protein contained α-tubulin was performed using a 
monoclonal anti-α-tubulin primary antibody (Sigma, St Louis, MO). For the putative 
GST-β-tubulin fusion protein, the presence of the GST carrier protein was confirmed 
using a monoclonal anti-GST antibody (Amersham Biosciences, Buckinghamshire, 
England) and confirmation that the fusion protein contained β-tubulin was performed 
using a monoclonal β-tubulin primary antibody (Sigma, St Louis, MO). An alkaline 
phosphatase-conjugated anti-mouse immunoglobulin G (IgG, whole molecule) (Sigma, 
St Louis, U.S.A.) was used as a secondary antibody for both fusion proteins. The 
conjugate was detected using a colorimetric alkaline phosphatase assay (Bio-Rad, 
Hercules, CA), performed as recommended by the manufacturer.   
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2.2.7  Purification of recombinant tubulin by affinity chromatography 
 
 
The MBP-α-tubulin fusion and MBP proteins were purified from the cell supernatant by 
affinity chromatography using amylose resin (New England Biolabs, Beverly, MA) 
under the manufacturer’s instructions with some modifications to attain the highest 
yield of soluble protein. Briefly, the recombinant protein was passed through the 
column twice to ensure maximal binding to the resin and the amount of NaCl in the 
column buffer was increased from 200mM to 500mM to prevent the protein 
precipitating once it was eluted from the column. In addition, during the elution step, 
the column was plugged after the elution buffer was loaded for at least 2hr to allow 
more time for the recombinant protein to separate from the amylose resin. This entire 
procedure was performed at 4
oC.  
 
The GST-β-tubulin fusion and GST proteins were purified using glutathione-agarose 
beads (Amersham Biosciences, Buckinghamshire, England) as per the manufacturer’s 
instructions with some modifications. Briefly, the recommended protein binding and 
elution times were increased to 18hr and the process was repeated twice using fresh 
glutathione beads to ensure the maximum yield of recombinant protein was obtained. 
This procedure was performed at 4
oC. 
 
SDS-PAGE, Western Blots and Dot Blots were performed (as described in 2.2.6) on the 
purified fusion proteins in order to determine the correct size of the proteins and 
whether the structural integrity of the proteins were preserved throughout the 
purification process. 
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The purified proteins were concentrated using Amicon Centripreps (Millipore, Billerica, 
MA) as recommended by the manufacturer and quantified using a Bio-Rad method 
based on the Bradford Method (1976). The concentration of the proteins was adjusted to 
approximately 1mg/ml with MBS buffer (0.1M MES pH 6.5, 0.2M sodium chloride, 
0.05% sodium azide, with 1mM phenylmethylsulfonyl fluoride (PMSF) protease 
inhibitor) and stored at –80
oC until required.  
 
Where possible recombinant α-tubulin was cleaved from MBP using the specific 
protease Factor Xa (New England Biolabs, Beverly, MA). Recombinant β-tubulin was 
cleaved from GST using PreScission Protease (Amersham Biosciences, 
Buckinghamshire, England). The cleaved tubulins were then purified from MBP or GST 
by anion-exchange chromatography using Uno-Q anion-exchange columns (Bio-Rad, 
Hercules, CA) at 4
oC. The eluents were analysed by SDS-PAGE and Western Blots as 
described previously and quantified using the Bio-Rad protein assay (Bradford, 1976). 
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2.3 Results 
 
 
2.3.1  Recombinant tubulin fusion protein expression 
 
 
The supernatant fractions of lysed E. coli samples were analysed by SDS-PAGE in 
order to establish the conditions required for the tubulin fusion proteins to be expressed 
in soluble form. The concentration of IPTG, incubation time and incubation temperature 
that provided the highest yield of soluble protein for MBP-α-tubulin fusion protein was 
0.1mM IPTG, for 5hr at 37
oC  and for GST-β-tubulin fusion protein was 0.1mM IPTG, 
for 4hr at 37
oC. The amount of soluble MBP-α-tubulin fusion protein produced 
increased steadily over a 5hr period and then plateaued after this time (Figure 2.3). After 
5hr of expression the ratio of soluble to insoluble protein decreased markedly. This 
pattern also occurs for GST-β-tubulin fusion protein, however, a shorter expression time 
of 4hr was found to be optimal (Figure 2.4).  
 
 
 
 
Figure 2.3 SDS-PAGE gel image illustrating MBP-α-tubulin fusion protein 
expression in soluble form over a 6hr time period. The time post-induction is 
shown above each lane.  
 
 
 
 
Figure 2.4 SDS-PAGE gel image illustrating GST-β-tubulin fusion protein 
expression in soluble form over a 6hr time period. The time post-induction is 
shown above each lane.  
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2.3.2  Recombinant tubulin fusion protein purification 
 
 
The presence of MBP and GST fusion protein tags has allowed the purification of α-
tubulin and β-tubulin using relatively straight forward affinity chromatography 
methods. Figure 2.5 depicts the course of the purification of MBP-α-tubulin fusion 
protein using the amylose resin column and Figure 2.6 depicts the course of the 
purification of GST-β-tubulin using the glutathione-agarose column. In Lane 2 of 
Figures 2.5 and 2.6, samples of the uninduced cultures in are shown to contain no fusion 
protein. Lanes 3 and 4 contain samples of the expressed fusion protein and soluble 
fraction of the fusion protein respectively. Lanes 5 in Figure 2.5 and Lanes 5 and 6 in 
Figure 2.6 contain samples of the flow-through from the columns showing the proteins 
that did not bind.  
 
 
 
Figure 2.5.  SDS-PAGE gel image illustrating the fractions from the purification of MBP-α-
tubulin fusion protein. Lane 1, protein MW standard; Lane 2, uninduced cells; Lane 3 total 
proteins produced in cells following 5 hours of expression; Lane 4 soluble proteins recovered 
from the supernatant of sonicated cells; Lane 5 flow through from the amylose column of 
proteins that did not bind; Lane 6, washing flow through confirming no target protein is being 
released from the resin at this stage and Lane 7, purified MBP-α-tubulin eluted from the 
amylose column of approximately 100kDa in size. 
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Washing the column with their respective column buffers did not elute any bound 
fusion protein as shown in Lane 6 in Figure 2.5 and Lanes 7 and 8 in Figure 2.6. The 
eluted MBP-α-tubulin fusion protein of size 100kDa is shown in Lane 7 in Figure 2.5 
and the eluted GST-β-tubulin fusion protein of size 75kDa is shown in Lanes 9 and 10.   
The SDS-Page gel picture in Figure 2.7 contains samples of the purified and 
concentrated recombinant MBP-α-tubulin, GST-β-tubulin, MBP and GST proteins of 
the correct size.  
 
 
 
 
 
 
 
 
Figure 2.6  SDS-PAGE gel image illustrating the fractions from the purification of GST-β-
tubulin fusion protein. Lane 1, protein MW standard; Lane 2, uninduced cells; Lane 3, total 
proteins produced in cells following 4 hours of expression; Lane 4 soluble proteins recovered 
from the supernatant of sonicated cells; Lanes 5 and 6, flow through from the glutathione-
agarose beads of proteins that did not bind; Lanes 7 and 8, washing flow through confirming no 
target protein is being released from the beads at this stage and Lane 9 and 10, purified GST-β-
tubulin eluted from the glutathione-agarose beads of approximately 75kDa in size. 
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Figure 2.7 SDS-PAGE gel image illustrating the purified soluble recombinant 
proteins and their relative sizes. 
 
 
 
 
2.3.3  Recombinant tubulin fusion protein analysis 
 
 
The Western (Figure 2.8) and Dot (Figure 2.9) Blots performed on purified fusion 
protein detected bands of the expected sizes for each recombinant protein demonstrating 
recognition by their respective monoclonal antibodies.  These results also indicate that 
the structural integrity of the tubulin fusion proteins has been preserved throughout the 
expression and purification processes.  
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Figure 2.8  Western Blot analysis of recombinant MBP-α-tubulin and GST-β-
tubulin a) MBP was detected using monoclonal anti-MBP antibody, b) α-tubulin 
was detected using monoclonal anti-α-tubulin antibody c) GST was detected using 
monoclonal anti-GST antibody and d) β-tubulin was detected using monoclonal 
anti-β-tubulin antibody. 
 
 
 
 
 
    
 
 
 
 
Figure 2.9  Dot Blot analysis of recombinant MBP-α tubulin and GST-β-tubulin. 
a) MBP was detected using monoclonal anti-MBP antibody, b) α-tubulin was 
detected using monoclonal anti-α-tubulin antibody c) GST was detected using 
monoclonal anti-GST antibody and d) β-tubulin was detected using monoclonal 
anti-β-tubulin antibody. 
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2.4 Discussion 
 
 
This is the first time the α-tubulin and β-tubulin genes from Trypanosoma brucei have 
been expressed in soluble form in E. coli. In previous studies, α- and β-tubulin from 
trypanosomes were expressed in an insoluble form in E. coli and attempts to solubilize 
the proteins were unsuccessful (Wu and Yarbrough, 1987). The development of fusion 
protein vectors during the 1990’s enables large quantities of soluble protein to be 
reliably produced (Sachdev and Chirgwin, 1998) with high levels of purity, which 
makes them suitable for characterisation studies such as drug-binding assays 
(MacDonald et al., 2003). 
 
Previous studies have shown that there is an optimal temperature, time and 
concentration of IPTG for expression of particular proteins with different fusion 
partners and that these should be determined empirically when optimising a protein 
expression system (MacDonald et al., 2003). MBP is generally more efficient than GST 
in increasing recovery of soluble protein (Kapust and Waugh, 1999; Sachdev and 
Chirgwin, 1998; Sachdev and Chirgwin, 2000; Smyth et al., 2003), however, for the 
expression of trypanosomal β-tubulin, this was not the case. The use of the pMAL 
protein expression and purification system only produced a small amount of soluble 
recombinant GST-β-tubulin fusion protein which may not be sufficient for 
characterisation experiments. In order to ensure that sufficient β-tubulin was produced, 
the pGEX protein expression and purification system was employed to produce 
recombinant  β-tubulin. The yield of soluble protein produced in this system was 
substantially increased.  
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Attempts to cleave the MBP and GST carrier proteins from tubulin using Factor Xa and 
PreScission protease respectively were only partially successful. Approximately 50% of 
the fusion protein was resistant to cleavage even after incubation for 24 hours with a 
ten-fold increase in concentration of enzymes.  This could have been due to use of 
specific protease that was inefficient or because the fusion protein was folded in such a 
way that the cleavage site was inaccessible to the protease. Although it is desirable to 
obtain pure recombinant tubulin protein for characterisation studies it is not essential 
because the attachment of MBP and GST to the N terminus of most proteins does not 
interfere with their function. The structure and tertiary folding of these carrier proteins 
are well characterised and many experiments have been conducted using purified but 
uncleaved fusion proteins (Sachdev and Chirgwin, 2000), including crystallization 
studies (Smyth et al., 2003). Furthermore, fusion partners can be advantageous in vivo 
because potentially they can protect the target protein from intracellular proteolysis 
(Sorensen and Mortensen, 2005), which would aid vaccine studies.  
 
Use of the pMAL and pGEX E. coli based protein expression and purification systems 
resulted in the production of soluble recombinant tubulin that is greater than 95% pure 
and free from post-translational modifications and microtubule-associated proteins. 
Tubulin generated in this manner is suitable for a number of applications, including 
drug-binding and vaccine studies. 
 
 
 
 
 
  
 
 
 
 
 
 
 
Chapter 3 
 
Investigation of the Interactions of Novel Trifluralin 
Analogues with Recombinant Tubulin from   
Trypanosoma brucei.  
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3.1 Introduction 
 
 
The dinitroanilines are tubulin-binding agents that were originally recognised for their 
herbicidal properties. Trifluralins and other dinitroaniline analogues (Figure 3.1) are 
used commercially for the elimination of grasses and broadleaf weeds (Chan and Fong, 
1994). They act by disrupting tubulin polymerization, inhibiting mitosis and causing a 
loss of orientation of cell wall microfibrils so that rectangular shaped cells become 
round (Chan et al., 1991; Chan et al., 1993). The anti-protozoal activity of the 
dinitroanilines has been demonstrated in vitro against a number of protozoan parasites 
including C. parvum (Armson et al., 1999b), Plasmodium sp. (Dow et al., 2002; Kaidoh 
et al., 1995), T. gondii (Morrissette et al., 2004; Stokkermans et al., 1996), Leishmania 
sp. and T. brucei (Chan and Fong, 1990; Chan et al., 1993), with low toxicity to 
mammalian cells.  
 
 
  
3.2 Material and Methods 
 
 
The underlying mode of action of the dinitroanilines has been studied extensively in T. 
gondii (Morrissette et al., 2004; Stokkermans et al., 1996). Recent studies showed that 
the dinitroaniline oryzalin bound consistently and with great affinity to α-tubulin from 
Figure 3.1 Structures of the major dinitroaniline compounds (Stokkermans et al., 1996).  
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T. gondii (Morrissette et al., 2004).  Moreover, oryzalin resistant Toxoplasma contained 
a single point mutation in the α-tubulin gene. A single point mutation in the α-tubulin 
gene was also found in the dinitroaniline resistant weed, Eleusine indica, (Anthony and 
Hussey, 1999). In contrast, most compounds that have been shown to interfere with 
microtubule function, such as the benzimidazoles, are known to bind to and act on β-
tubulin (Nogales, 2000).  
 
Interestingly, the activity of dinitroanilines is restricted to plants and protozoa. These 
compounds are ineffective against mammalian or fungal microtubules (Bajer and Mole-
Bajer, 1986; Chan and Fong, 1990; Dow et al., 2002; Hess and Bayer, 1977; Hugdahl 
and Morejohn, 1993). A novel oryzalin analogue called GB-II-5 has recently been 
synthesised that shows potent, selective antimitotic activity against L. donovani and T. 
brucei (Werbovetz et al., 2003). GB-II-5 is a proven tubulin binding compound and 
further supports the suggestion that analogues of dinitroanilines are strong candidates as 
chemotherapeutic compounds against trypanosomiasis infection (Bhattacharya et al., 
2004). 
 
The kinetics of the binding of trifluralin and its analogues to trypanosomal tubulin have 
not been determined to date mainly because of the difficulty in extracting homogenous 
tubulin from trypanosomes free from microtubule-associated proteins. The successful 
production of recombinant α- and β-tubulin from T. b. rhodesiense (Chapter 2) has 
enabled such binding studies. The fluorescence quenching technique is based on 
measuring the reduction of intrinsic fluorescence from tryptophan residues as a result of 
the binding of compounds directly with or close to tryptophan residues. Fluorescence 
quenching has been successfully applied to determine the binding kinetics of colchicine  
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(Banerjee and Luduena, 1992; Chaudhuri et al., 2000) and taxol (Diaz et al., 2000; Han 
et al., 1996) to mammalian tubulin. Most recently, fluorescence quenching was 
successfully used to quantify the kinetics of binding of benzimidazoles to tubulin from 
G. duodenalis, E. intestinalis, C. parvum (Macdonald et al., 2004) and P. falciparum 
(Low, 2005) and of dinitroaniline compounds to tubulin from Leishmania and T. brucei 
(Werbovetz et al., 1999; Werbovetz et al., 2003). 
 
 
The aim of this study was: 
 
1.  To quantify the kinetics of binding of novel trifluralin 
analogues to recombinant tubulin from T. b. rhodesiense. 
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3.2  Materials and Methods 
 
 
3.2.1  Expression of recombinant trypanosomal tubulin 
 
 
The expression and purification of α-tubulin and β-tubulin proteins from T. b. 
rhodesiense has been previously described (see Chapter 2). The recombinant α- and β-
tubulin fusion proteins were maintained in MBS (0.1M MES pH 6.5, 0.2M sodium 
chloride, 0.05% sodium azide, 1mM PMSF) at a concentration of 1mg/ml and kept at    
–80
oC until required for use. 
 
 
3.2.2  Extraction of native rat brain tubulin 
 
 
Tubulin was extracted from the brains of rats (Rattus norvegicus) using a modification 
of the method of Castoldi and Popov (2003). Eight euthanased rats were obtained from 
the Animal Resource Centre (Murdoch University) and their brains removed, stored in 
ice-cold PBS (20mM Na2PO4, 150mM NaCl, pH 7.2) and the tubulin extracted within 
24hr. The brains were cleaned of blood clots and surrounding meningeal membranes in 
PBS and weighed. Cold (+4
oC) depolymerisation buffer (DB) (50mM MES, 1mM 
CaCl2, pH 6.6) was added at a ratio of 1ml/g brain tissue. The brains were cut into small 
pieces with scissors, placed into 15ml centrifuge tubes and homogenized using an Ultra 
Turax T25 homogenizer (Kika Works, Malaysia) twice for 30sec with a 20sec rest 
period. The homogenates were centrifuged at 29,000 ×  g for 60min at 4
oC. The 
supernatants were harvested, pooled and an equal volume of warm (37
oC) high-molarity 
PIPES buffer (1M PIPES, 10mM MgCl2, 20mM EGTA, pH 6.9), ATP (1.5mM final 
concentration) and GTP (0.5mM final concentration) was added. An equal volume (1/3 
of the final volume) of pre-warmed (37
oC) anhydrous glycerol was also added to this 
solution. This mixture was incubated in a 37
oC water bath for 1hr to allow the tubulin to  
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polymerise. The polymerised tubulin was then centrifuged at 100,000 × g for 30min at 
37
oC. The resulting microtubule pellet was resuspended in 20ml of cold (4
oC) DB and 
incubated on ice for 30min to allow the tubulin to depolymerise. The suspension of 
depolymerised tubulin was centrifuged at 70,000 × g for 30min at 4
oC and the 
supernatant containing soluble tubulin was collected. A sample of the tubulin extracted 
from rat brain was analysed using SDS-PAGE (performed as previously described in 
Chapter 2) and Western and Dot Blots using monoclonal anti-α-tubulin primary 
antibody and monoclonal anti-β-tubulin primary antibody (Sigma, St Louis, MO). The 
solution of rat tubulin was quantified using the Bio-Rad Protein assay (Bradford, 1976), 
concentrated using Amicon centripreps (Millipore, Billerica, MA) and maintained in 
MBS at a concentration of approximately 1mg/ml. It was stored at –80
oC until required 
for use.  
 
 
3.2.3  Novel trifluralin analogues 
 
 
Novel analogues of trifluralin EPL-AJ1003 (1003), EPL-AJ1007 (1007), EPL-AJ1008 
(1008), EPL-AJ1016 (1016), and EPL-AJ1017 (1017) were synthesized and supplied by 
Epichem Pty. Ltd (Murdoch, WA). Compounds 1003, 1007, 1016 and 1017 are second 
generation trifluralin analogues. These analogues have in common  a 2,4-dinitro-6-
(trifluoromethyl)phenyl moiety and differ  in the substituents at the C1 position of 
the  phenyl ring (Figure 3.2). Compound 1008 is a third generation analogue of 
trifluralin and now considered to be a bi-phenyl compound because its chemical 
composition is considerably different from the other analogues. This compound is not 
patented and therefore, permission to publish the chemical composition has not been 
granted.   
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                                EPL-AJ1003                  EPL-AJ1007 
                                                                                                                           
                                                                                                                        
       
                                                                                                                 
  EPL-AJ1016    EPL-AJ1017 
                                                                                                                          
                                                                                                                        
Figure 3.2 Structures of second generation analogues of trifluralin 
(Epichem Pty. Ltd.).  
 
 
Albendazole and trifluralin were also supplied by Epichem Pty. Ltd., and colchicine was 
purchased from Sigma (St Louis, MO). Stock solutions of these compounds were 
prepared in 100% dimethyl sulphoxide (DMSO) at a concentration of 1mM and stored 
in 50μl aliquots at –20
oC until required for use. 
 
 
3.2.4  Fluorescence Quenching Assay  
 
 
The interaction of each test compound with recombinant trypanosomal α- and β-tubulin 
and native rat brain tubulin was measured as the amount of reduction in the intrinsic 
fluorescence of tryptophan residues following incubation with each compound. An 
initial binding study was performed by incubating 2μM concentrations of each 
compound and 2μM concentrations of each tubulin subtype at 37
oC for 30min. 
Fluorescence was immediately measured in a quartz cuvette (Starna Pty Ltd) with 
excitation and emission path lengths of 10mm using a Luminescence spectrometer LS50  
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(Perkin Elmer) at excitation wavelength of 280nm and emission wavelengths of 350nm 
for MBP-α-tubulin, MBP and GST, 340nm for native rat tubulin and 330nm for GST-β-
tubulin (initially optimised over a 300-400nm range for each protein).  
 
The fluorescence measurements were corrected for inner-filter effects (caused by the 
addition of each compound) according to Mertens and Kagi (Mertens and Kagi, 1979) 
as follows: 
 
Fcorr = Ffobs.antilog 
(Ax + Am)/2 
 
 
where Fcorr  is the corrected fluorescence intensity, Ffobs is the observed intensity and Ax 
and Am are the measured absorbances at the excitation and emission wavelengths, 
respectively. The corrected fluorescence values were then used to determine the 
percentage reduction of fluorescence intensity using the fluorescence value of the 
DMSO control as the maximum value. Each compound was tested in triplicate and 
controls of MBS, 5% DMSO in MBS, test compounds in MBS, MBP fusion tag protein 
in MBS and GST fusion tag protein in MBS were also tested.  
 
 
3.2.5  Equilibrium Binding Assay 
 
 
Equilibrium binding was determined by measuring the reduction in fluorescence 
intensity of recombinant trypanosomal α- and β-tubulin and native rat brain tubulin 
following incubation with a range of concentrations (0.1, 0.2, 0.5, 1, 2, 5 and 10μM) of 
each compound. Each concentration of compound was incubated with 2μM of tubulin 
for 30min at 37
oC and fluorescence was immediately measured following the same 
conditions as previously described (3.2.4). Data obtained was used to generate binding  
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curves for comparisons between the two forms of recombinant trypanosomal tubulins 
and native rat tubulin. Each compound was tested in triplicate and controls of MBS 
alone, 5% DMSO in MBS, test compound in MBS, MBP fusion tag protein in MBS and 
GST fusion tag in MBS were also tested.   
 
 
3.2.6  Binding Kinetics Study  
 
 
The kinetics of novel analogues of trifluralin (EPL-AJ 1003, 1007, 1008, 1016 and 
1017), trifluralin, albendazole and colchicine with recombinant trypanosomal tubulins 
and native rat brain tubulin were determined under pseudo-first order conditions. 
Association rates were determined by measuring the reduction in fluorescence following 
the incubation of 2μM concentrations of test compounds to 2μM concentrations of 
recombinant trypanosomal tubulin and native rat tubulin, at 37
oC. The amount of 
fluorescence was measured every 5min for 30min. This study was performed following 
the same conditions as previously described (3.2.4). Each compound was tested in 
triplicate and controls of MBS, 5% DMSO in MBS, test compound in MBS, MBP 
fusion tag protein in MBS and GST fusion tag protein in MBS were also tested.   
 
Data were analysed using a non-linear curve fitting analysis and a one-site binding 
equation according to (Bane et al., 1984; Chakrabarti et al., 1996; Chaudhuri et al., 
2000; Lambeir and Engelborghs, 1981; Pyles and Hastie, 1993). The association rate 
(kon) was calculated using the change in fluorescence (Fmax − F t) attributable to the 
binding of each compound as follows: 
(Fmax − Ft  ) = Ae 
−αt 
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where Fmax is maximum fluorescence intensity, Ft is the fluorescence intensity at time t, 
A is the amplitude of the binding phase and α is the observed rate constant of the 
binding phase. The parameters A and α can be determined from the logarithmic plot of 
ln(Fmax - Ft) against time t.  
 
The apparent association constant (kon) for each compound was calculated as follows:  
 
kon  = α / [D] 
 
where α is the slope of the semi-logarithmic binding plot and D is the concentration of 
the compound tested. 
 
Dissociation rates (koff) were determined by measuring the change in fluorescence 
following a 200-fold dilution of each compound-tubulin complex by tubulin in MBS 
and monitoring the increase in fluorescence as the compounds were released from their 
binding sites. The dissociation rate constant was determined using the equation: 
 
 
ln(Fmax − Ft) = -koff t + C 
 
where C is the integration constant. 
 
The affinity constant (Ka) was determined for each compound with each tubulin 
according to the formula: 
Ka = kon / koff 
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3.2.7  Analysis of the tubulin amino acid sequences from T. b. rhodesiense, L.         
            major, Rattus norvegicus and Homo sapiens 
 
 
Amino acid sequences for α-tubulins from four different species were obtained from the 
following references: T. b. rhodesiense (Kimmel et al., 1985), L. major (Ivens et al., 
1998), R. norvegicus (Strausberg et al., 2002) and H. sapiens (Strausberg et al., 2002).  
Amino acid sequences for β-tubulins from the same species were obtained from the 
following references: T. b. rhodesiense (Kimmel et al., 1985), L. major (Ivens et al., 
1998), R. norvegicus (Ginzburg et al., 1985) and H. sapiens (Shiina et al., 2001). These 
sequences were manually aligned using Microsoft Word and the percent homology 
between the sequences were calculated manually.   
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3.3 Results 
 
 
3.3.1  Native rat brain tubulin extraction and analysis 
 
 
Soluble tubulin extracted from rat brains was approximately 50kDa in size and free 
from impurities as shown in Figure 3.3. 
 
 
   
 
 
 
Figure 3.3 SDS-PAGE gel image illustrating the size and relative 
purity of native tubulin extracted from rat brains. 
 
 
Western and Dot Blot analysis performed using both monoclonal anti-α-tubulin and 
anti-β-tubulin antibodies (Figure 3.4) indicate that the structural integrity of the rat 
tubulin was maintained throughout the extraction process. 
 
            
           a           b 
Figure 3.4 a) Western Blot and b) Dot Blot analysis of native tubulin 
extracted from rat brains using monoclonal anti-α-tubulin and anti-β-
tubulin antibodies. 
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3.3.2  Effect of Test Compounds on Tubulin Fluorescence 
 
  
All five of the novel trifluralin compounds and commercial trifluralin significantly 
reduced the fluorescence intensity of recombinant trypanosomal α-tubulin (57-84%) at 
2μM (Figure 3.5). In comparison, test compounds 1008, 1007 and 1017 and albendazole 
induced moderate reductions in the fluorescence intensity of recombinant trypanosomal 
β-tubulin (29-58%). Compounds 1003 and 1016 induced only low reductions in 
fluorescence intensity of recombinant trypanosomal β-tubulin (1-14%). In contrast, 
compound 1003 induced a significant reduction (63%) and colchicine induced a 
moderate reduction (42%) in the fluorescence intensity of native rat brain tubulin. 
Compounds 1016 and 1008 and 1017 did not alter the fluorescence intensity of native 
rat brain tubulin and compound 1007 induced a low reduction in fluorescence intensity 
(11%).  
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Figure 3.5 The proportion of tubulin fluorescence that was quenched following the addition of 
2μM concentrations of test compounds; Colchicine (Colch), Trifluralin (Trif), Albendazole 
(ABZ), EPL-AJ1003 (1003), EPL-AJ1016 (1016), EPL-AJ1008 (1008), EPL-AJ1007 (1007) 
and EPL-AJ1017 (1017) to recombinant trypanosomal α-tubulin (a-tubulin), recombinant 
trypanosomal β-tubulin (b-tubulin) and native rat brain tubulin (rat tubulin).  
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3.3.3  Equilibrium Binding of Test Compounds with Tubulin 
 
 
All five of the novel trifluralin compounds interacted with recombinant trypanosomal α-
tubulin and quenched fluorescence in a concentration-dependent manner (Figure 3.6). 
The binding curves generated for the interaction of compounds 1003, 1016, 1017 and 
commercial trifluralin with α-tubulin show a hyperbola shape. Compounds 1007 and 
1008 each exhibit distinct binding curves. Saturation of compound-tubulin complexes 
was achieved at concentrations between 0.5μM and 2μM as demonstrated by the 
plateau in the curves. A return in fluorescence occurs following saturation point due to 
the high concentrations of compounds exhibiting strong intrinsic fluorescence and/or 
conformational changes occurring in α-tubulin causing dissociation of compounds.  
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Figure 3.6 Equilibrium binding of test compounds Trifluralin (Trif), EPL-AJ1003, 
1007, 1008, 1016 and 1017 with recombinant trypanosomal α-tubulin. 
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In contrast, the compounds tested on recombinant trypanosomal β-tubulin exhibited 
varying curve shapes for each test compound (Figure 3.7). Compounds 1003 and 1016 
induced low reductions in fluorescence intensity of β-tubulin that did not change with 
increasing concentrations of compounds. The binding curve generated by compound 
1008 did not follow a concentration-dependent trend. Compounds 1007 and 1017 
interacted with recombinant trypanosomal β-tubulin and quenched fluorescence in a 
concentration-dependent manner with a plateau between 1μM and 5μM concentrations 
similar to albendazole. A return in fluorescence occurred following saturation point due 
to the high concentrations of compounds exhibiting strong intrinsic fluorescence and/or 
conformational changes occurring in β-tubulin causing dissociation of compounds.  
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Figure 3.7 Equilibrium binding of test compounds Albendazole (ABZ), EPL-
AJ1003, 1007, 1008, 1016 and 1017 with recombinant trypanosomal β-tubulin. 
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Compounds 1017 and 1007 caused small percentage reductions in rat brain tubulin 
fluorescence that were not concentration-dependent (Figure 3.8). Compounds 1008 and 
1016 did not alter the fluorescence intensity of native rat brain tubulin. Compound 1003 
induced a significant reduction in fluorescence that was concentration-dependent 
without the development of a plateau even at the maximum concentration of 10μM. 
Colchicine induced a concentration-dependent reduction in the fluorescence intensity of 
native rat tubulin with saturation of the complex occurring between 1μM and 5μM 
concentrations as shown in the plateau of the hyperbolic curve, followed by a return in 
fluorescence. 
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Figure 3.8 Equilibrium binding of test compounds Colchicine (Colch), EPL-
AJ1003, 1007, 1008, 1016 and 1017 with native rat brain tubulin. 
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3.3.4 Kinetics  of  Trifluralin Binding to Tubulin 
 
 
The semi-logarithmic plots of the association of each compound with recombinant 
trypanosomal α- and β-tubulin and native rat brain tubulin are shown in Figures 3.9-
3.13. Association rates could not be calculated for the binding of compounds 1008, 
1016 and 1017 with native rat brain tubulin because these compounds did not reduce the 
fluorescence intensity of rat brain tubulin (see Figures 3.5 and 3.8). The association 
rates for the binding of each compound with recombinant trypanosomal α-tubulin were 
in the range of 1.22 to 2.38 × 10
4 M
-1min
-1 (Table 3.1), which is higher than the 
association with recombinant trypanosomal β-tubulin and native rat brain tubulin which 
were in the range of 2.00 × 10
2 to 1.01 × 10
4 M
-1min
-1 (Table 3.2) and 1.65 × 10
3 to 1.19 
10
4 M
-1min
-1 respectively (Table 3.3).   
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Figure 3.9 Semi-logarithmic plot of the associations of compound 1008 with 
recombinant trypanosomal α- and β-tubulin. (N.B. Compound 1008 did not induce 
a reduction of the fluorescence of native rat brain tubulin). 
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Figure 3.10 Semi-logarithmic plot of the associations of compound 1016 with 
recombinant trypanosomal α- and β-tubulin. (N.B. Compound 1016 did not induce 
a reduction of the fluorescence of native rat brain tubulin). 
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Figure 3.11 Semi-logarithmic plot of the associations of compound 1007 with 
recombinant trypanosomal α- and β-tubulin and native rat brain tubulin. 
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Figure 3.12 Semi-logarithmic plot of the associations of compound 1017 with 
recombinant trypanosomal α- and β-tubulin and native rat tubulin. (N.B. 
Compound 1017 did not induce a reduction of the fluorescence of native rat brain 
tubulin). 
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Figure 3.13 Semi-logarithmic plot of the associations of compound 1003 with 
recombinant trypanosomal α- and β-tubulin and native rat brain tubulin. 
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The semi-logarithmic plots of the dissociation of each compound with recombinant 
trypanosomal α- and β-tubulin and native rat tubulin are shown in Figures 3.14-3.18. 
The dissociation rates for the binding of each of each compound with recombinant 
trypanosomal α-tubulin were in the range of 1.70 to 3.81 × 10
-2 min
-1 (Table 3.1), which 
is lower compared to the dissociation rates for binding to recombinant trypanosomal β-
tubulin, which were in the range of 6.0 × 10
-4 to 3.93 × 10
-2 min
-1 (Table 3.2). The 
dissociation rates for the binding of compounds 1003 and 1008 to recombinant 
trypanosomal β-tubulin could not be determined because neither compound reduced 
fluorescence initially (Table 3.2).  Dissociation rates for colchicine and compound 1003 
with native rat tubulin were 3.38 × 10
-2 min
-1 and 5.62 × 10
-2 min
-1 respectively (Table 
3.3). The dissociation rate could not be determined for compound 1007 with native rat 
tubulin because fluorescence increased beyond the Fmax value.  
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Figure 3.14 Semi-logarithmic plot of the dissociation of compound 1008 from 
recombinant trypanosomal α-tubulin. 
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Figure 3.15 Semi-logarithmic plot of the dissociations of compound 1016 from 
recombinant trypanosomal α- and β-tubulin. 
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Figure 3.16 Semi-logarithmic plot of the dissociations of compound 1007 from 
recombinant trypanosomal α- and β-tubulin. 
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Figure 3.17 Semi-logarithmic plot of the dissociations of compound 1017 from 
recombinant trypanosomal α- and β-tubulin. 
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Figure 3.18 Semi-logarithmic plot of the dissociations of compound 1003 from 
recombinant trypanosomal α-tubulin and native rat brain tubulin. 
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The affinity constants (Ka) for the binding of the novel trifluralin analogues, trifluralin, 
albendazole and colchicine to recombinant trypanosomal α- and β-tubulin and native rat 
brain tubulin are shown in Tables 3.1 to 3.3. Affinity constants for the binding of each 
compound with recombinant trypanosomal α-tubulin were in the range 3.20 × 10
5 to 
1.23  × 10
6 M
-1  (Table 3.1), which is significantly higher compared to the affinity 
constants for binding to recombinant trypanosomal β-tubulin and native rat tubulin 
which were in the range of 1.50 to 3.33 × 10
5 M
-1 (Table 3.2) and 2.12 to 2.90 × 10
5 M
-1 
(Table 3.3) respectively.  
 
 
 
 
 
Table 3.1 The association (kon), dissociation (koff) and affinity (Ka) constants for the 
binding of trifluralin analogues with recombinant trypanosomal α-tubulin. 
                                                                                                                                            
   Trifluralin     Binding Parameter  
   analogue                                                                                                                   
   kon (M
-1 min
-1)       koff (min
-1)       Ka (M
-1) 
                                                                                                                                                         
   1003       1.85 × 10
4       1.70 × 10
-2        1.09 × 10
6 
   1007       2.38 × 10
4       1.93 × 10
-2       1.23 × 10
6 
   1008       1.50 × 10
4       3.16 × 10
-2       4.75 × 10
5 
   1016       1.66 × 10
4       2.40 × 10
-2       6.92 × 10
5 
   1017       1.22 × 10
4       3.81 × 10
-2       3.20 × 10
5 
   Trif.       1.27 × 10
4       1.64 × 10
-2       7.74 × 10
5 
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Table 3.2 The association (kon), dissociation (koff) and affinity (Ka) constants for the 
binding of trifluralin analogues and albendazole with recombinant trypanosomal β-
tubulin. 
                                                                                                                                                     
   Trifluralin     Binding Parameter  
   analogue                                                                                                                   
   kon (M
-1 min
-1)       koff (min
-1)       Ka (M
-1) 
                                                                                                                                                         
   1003       4.50 × 10
2 
       -                                      -   
     1007       1.01 × 10
4       5.13 × 10
-2       1.97 × 10
5 
   1008       3.95 × 10
3         -
              - 
   1016       2.00 × 10
2       6.00 × 10
-4      3.33 × 10
5 
   1017       7.65 × 10
3       3.93 × 10
-2       1.95 × 10
5 
   ABZ       5.50 × 10
3       3.67 × 10
-2       1.50 × 10
5 
                                                                                                                                                  
 
 
 
Table 3.3 The association (kon), dissociation (koff) and affinity (Ka) constants for the 
binding of trifluralin analogues and colchicine with native rat brain tubulin. 
                                                                                                                                             
   Trifluralin     Binding Parameter  
   analogue                                                                                                              
   kon (M
-1 min
-1)       koff (min
-1)       Ka (M
-1) 
                                                                                                                                                    
   1003       1.19 × 10
4 
     5.62 × 10
-2        2.12 × 10
5 
     1007       1.65 × 10
3        -  
        - 
   Colch.     9.80 × 10
3       3.38 × 10
-2       2.90 × 10
5 
                                                                                                                                                           
 
 
 
3.3.5  Analysis of the tubulin amino acid sequences from T. b. rhodesiense, L.         
            major, Rattus norvegicus and Homo sapiens 
 
 
There is 94.5% homology between the amino acid sequences of trypanosomal and 
leishmanial  α-tubulin  and 85% homology between trypanosomal and rat α-tubulin 
(Figure 3.19). There is 95.2% and 83.7% homology between the amino acid sequences 
of trypanosomal and leishmanial β-tubulin and trypanosomal and rat β-tubulin 
respectively (Figure 3.20). Homology between rat and human α- and β-tubulin is 99.3% 
and 95% respectively.  
Chapter 3. Binding Kinetics of Trifluralin Analogues 
  87
 
 
                                     21                               
T.brucei  MREAICIHIG  QAGCQVGNAC  WELFCLEHGI  QPDGAMPSDK  TIGVEDDAFN  
L.major  MREAICIHIG  QAGCQVGNAC  WELFCLEHGI  QPDGSMPSDK   CIGVEDDAFN   
R.norv  MRECISIHVG  QAGVQIGNAC  WELYCLEHGI  QPDGQMPSDK  CIGGGDDSFN  
H.sapien  MRECISIHVG  QAGVQIGNAC  WELYCLEHGI  QPDGQMPSDK  CIGGGDDSFN 
                          *  *    *            *   *                    *                          *              *     **     *      
  51                         81 
T.brucei  TFFSETGAGK  HVPRAVFLDL EPTVVDEVRT GTYRGLFHPE  GLISGKEDAA 
L.major  TFFSETGAGK  HVPRCIFLDL   EPTVVDEVRT GTYRGLFHPE  GLVSGKEDAA 
R.norv  TFFSETGAGK  HVPRCIFLDL   EPTVVDEVRT GTYRILFHPE   GLQTGKEDAA 
H.sapien  TFFSETGAGK  HVPRCIFVDL   EPTVIDEVRT  GTYRQLFHPE  GLQTGKEDAA 
                                                     **  *                *                        *                  ** 
             111                          141           
T.brucei  NNYARGHYTI  GKEIVDLCLD  RIRKLADNCT  GLQGFLVYHA  VGGGTGSGLG 
L.major  NNYARGHYTI  GKEIVDLALD  RIRKLADNCT  GLQGFMVFHA  VGGGTGSGLG      
R.norv  NNYARGHYTI  GKEIIDLVLD   RIRKLADQCT  GLQGFMVFHS   FGGGTGSGFT   
H.sapien  NNYARGHYTI  GKEIIDLVLD   RIRKLADQCT  GLQGFMVFHS   FGGGTGSGFT  
                                                     *    *                        *                    *   *  *   *                  ** 
                     171 
T.brucei  ALLLERLSVD  YGKKSKLGYT  VYPSPQVSTA  VVEPYNSVLS  THSLLEHTDV 
L.major  ALLLERLSVD  YGKKSKLGYT  VYPSPQVSTA  VVEPYNCVLS  THSLLEHTDV  
R.norv  SLLMERLSVD  YGKKSKLEFS    IYPAPQVSTA   VVEPYNIVLT  THTTLEHSDC   
H.sapien  SLLMERLSVD  YGKKSKLEFS    IYPAPQVSTA   VVEPYNIVLT  THTTLEHSDC   
  *     *                                  ***   *     *                               **  *        **       *  
  201           231 
T.brucei  AAMLDNEAIY  DLTRRNLDIE  RPTYTNLNRL IGQVVSSLTA  SLRFDGALNV 
L.major  ATMLDNEAIY  DLTRRSLDIE  RPSYTNVNRL  IGQVVSSLTA  SLRFDGALNV 
R.norv  AFMVDNEAIY  DICRRSLDIE   RPSYTNVNRL  IGQIVSSITA    SLRFDGALNV 
H.sapien  AFMVDNEAIY  DICRRSLDIE   RPSYTNVNRL   ISQIVSSITA    SLRFDGALNV 
     *                       **     *               *        *            *  *     * 
           261                        291 
T.brucei  DLTEFQTNLV  PYPRIHFVLT  SYAPVISAEK  AYHEQLSVSE   ISNAVFEPAS 
L.major  DLTEFQTNLV  PYPRIHFVLT  SYAPVVSAEK AYHEQLSVAD  ITNSVFEPAG 
R.norv  DLTEFQTNLV  PYPRIHFPLA  TYAPVISAEK  AYHEQLSVAD  ITNSCFEPAN 
H.sapien  DLTEFQTNLV  PYPRIHFPLA  TYAPVISAEK  AYHEQLSVAD  ITNSCFEPAN 
                                          *  *   *         *                               **    *   * *        * 
      321 
T.brucei  MMTKCDPRHG  KYMACCLMYR  GDVVPKDVNA  AVATIKTKRT IQFVDWSPTG  
L.major  MLTKCDPRHG   KYMSCCLMYR  GDVVPKDVNA   AIATIKTKRT  IQFVDWCPTG 
R.norv  QLVKCDPRHG   KYMSCCLLYR   GDVVPRDVNA   AIATIKTKRT   IQFVDWCPTG 
H.sapien  QLVKCDPRHG   KYMSCCLLYR   GDVVPKDVNA   AIATIKTKRS   IQFVDWCPTG 
                   *   *                            *       *                     *               *                *                 * 
  351                 381 
T.brucei  FKCGINYQPP  TVVPGGDLAK  VQRAVCMIAN   STAIAEVFAR   IDHKFDLMYS 
L.major  FKCGINYQPP  TVVPGGDLAK  VQRAVCMIAN   STAIAEVFAR   IDHKFDLMYS 
R.norv  FKVGINYQPP  TVVPGGDLAK  VQRAVCMLSN  TTAIAEAWAR  ILHKFDLMYA 
H.sapien  FKVGINYQPP  TVVPGGDLAK  VQRAVCMLSN  TTAIAEAWAR  ILHKFDLMYA 
       *                                                               **    *           * *         *                  * 
             411                               441 
T.brucei KRAFVHWYVG  EGMEEGEFSE AREDLAALEK  DYEEVGAESA  DMDGEEDVEE Y           
L.major  KRAFVHWYVG EGMEEGEFSE AREDLAALEK  DYEEVGAESA  DDMGEEDVEE Y 
R.norv  KRAFVHWYVG EGMEEGEFSE AREDMAALEK DYEEVGVDSV  EGEGEE EGEE Y 
H.sapien  KRAFVHWYVG EGMEEGEFSE AREDMAALEK DYEEVGVDSV  EGEGEE EGEE Y 
                                                                *                            * *   *  ***         ** 
  
          
 
Figure 3.19 Comparison of amino acid sequences of α-tubulin from T. b. rhodesiense (Kimmel 
et al., 1985), Leishmania major (Ivens et al., 1998), Rattus norvegicus (Strausberg et al., 2002) 
and Homo sapiens (Strausberg et al., 2002). (N.B. * areas of variability). 
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                                                                                                                                             21  
T.brucei  MREIVCVQAG  QCGNQIGSKF  WEVISDEHGV  DPTGTYQGDS  DLQLERINVY  
L.major    MREIVSCQAG   QCGNQIGSKF  WEVISDEHGV  DPTGTYQGDS  DLQLERINVY 
R.norv  MREIVHIQAG   QCGNQIGPKF   WEVISDEHGI   DPTGSYHGDS   DLQLERINVY  
H.sapien  MREIVHIQAG   QCGNQIGAKF   WEVISDEHGI   DPTGSYHGDS  DLQLDRISVY 
                              **                           *                            *            *   *                   *    * 
  51                  81 
T.brucei  FDEATGGRYV  PRSVLIDLEP    GTMDSVRAGP  YGQIFRPDNF   IFGQSGAGNN  
L.major  FDESTGGRYV   PRAVLMDLEP GTMDSVRAGP  YGQLFRPDNF  IFGQSGAGNN 
R.norv  YNESAGGNKV  PRAILVDLEP   GTMDSVRSGP   FGQLFRPDNF  VFGQSGAGNN  
H.sapien  YNESAGGNKV  PRAILVDLEP   GTMDSVRSGP   FGQLFRPDNF  VFGQSGAGNN 
  * *   * *      * *           **   *                                 *        *      *                  *  
               111                                141 
T.brucei  WAKGHYTEGA  ELIDSVLDVC   CKEAESCDCL  QGFQICHSLG  GGTGSGMGTL 
L.major  WAKGHYTEGA  ELIDSVLDVC   RKEAESCDCL  QGFQLSHSLG  GGTGSGMGTL 
R.norv  WAKGHYTEGA  ELVDSVLDVV  RKESESCDCL  QGFQLTHSLG  GGTGSGMGTL  
H.sapien  WAKGHYTEGA  ELVDSVLDVV  RKESESCDCL  QGFQLTHSLG  GGTGSGMGTL  
                                      *                 *   *      *                             * *                     
                 171 
T.brucei  LISKLREQYP  DRIMMTFSII     PSPKVSDTVV   EPYNTTLSVH   QLVENSDESM 
L.major  LISKLREEYP  DRVMMTFSII    PSPRVSDTVV   EPYNTTLSVH   QLVENSDESM 
R.norv  LISKIREEYP   DRNMMVMSII  PSPKVSDTVV   EPYNATLSVH   QLVENTDETY 
H.sapien  LISKIREEYP   DRNMMVVSII   PSPKVSDTVV   EPYNATLSVH   QLVENTDETY 
           *    *             *       **              *                           *                           *      ** 
  201         231 
T.brucei  CIDNEALYDI  CFRTLKLTTP  TFGDLNHLVS   AVVSGVTCCL   RFPGQLNSDL 
L.major  CIDNEALYDI  CFRTLKLTTP  TFGDLNHLVA   AVMSGVTCCL  RFPGQLNSDL  
R.norv  CIDNEALYDI  CFRTLKLTTP  TYGDLNHLVS   ATMSGVTTCL  RFPGQLNADL 
H.sapien  CIDNEALYDI  CFRTLKLTTP  TYGDLNHLVS   ATMSGVTTCL  RFPGQLNADL 
                                                     *                 *      **           *                       * 
            261                             291 
T.brucei  RKLAVNLVPF   PRLHFFMMGF APLTSRGSQQ  YRGLSVPELT  QQMFDAKNMM 
L.major  RKLAVNLVPF   PRLHFFMMGF APLTSRGSQQ  YRGLSVPELT  QQMFDAKNMM 
R.norv  RKLAVNMVPF  PRLHFFMPGF  APLTSRGSQQ   YRALTVPELT  QQMFDSKNMM  
H.sapien  RKLAVNMVPF  PRLHFFMPGF  APLTSRGSQQ   YRALTVPELT  QQVFDAKNMM 
                                  *                          *                                      *  *                   *      * 
                     321 
T.brucei  QAADPRHGRY  LTASALFRGR  MSTKEVDEQM  LNVQNKNSSY   FIEWIPNNIK  
L.major  QAADPRHGRY  LTASALFRGR  MSTKEVDEQM  LNVQNKNSSY   FIEWIPNNIK  
R.norv  AACDPRHGRY  LTVAAIFRGR  MSMKEVDEQM  LNVQNKNSSY   FVEWIPNNVK 
H.sapien  AACDPRHGRY  LTASAVFRGR MSMKEVDEQM  LNVQNKNSSY   FVEWIPNNVK 
                   *  *                         * *  *                  **                                              *               * 
  351       381 
T.brucei  SSVCDIPPKG  LKMAVTFIGN  NTCIQEMFRR  VGEQFTLMFR   RKAFLHWYTG  
L.major  SSICDIPPKG   LKMSVTFIGN   NTCIQEMFRR  VGEQFTGMER   RKAFLHWYTG   
R.norv  TAICDIPPRG   LKMSATFIGN   STAIQELFKR   ISGEQFTAMER  RKAFLHWYTG 
H.sapien  TAICDIPPRG   LKMAVTFIGN  STAIQELFKR   ISGEQFTAMER  RKAFLHWYTG   
  * *             *                * *              *   *       *   *     **             *    * 
                  411                                               441 
T.brucei EGMDEMEMEFTE  AESNMNDLVS   EYQQYQDATI    EEEGEFDEEE  QY                 
L.major  EGMDEMEMEFTE  AESNMNDLVS   EYQQYQDATV  EEEGEYDEEE  EAY 
R.norv  EGMDEMEMEFTE  AESNMNELVS   EYQQYQDATA   DEQGEYEEEE GEDEA 
H.sapien  EGMDEMEMEFTE  AESNMNDLVS   EYQQYQDATA   DEQEDYGEEA EEEA 
                                                 *                                 *   *  * * * **    *  ***** 
               
        
 
Figure 3.20 Comparison of amino acid sequences of β-tubulin from T. b. rhodesiense (Kimmel 
et al., 1985), Leishmania major (Ivens et al., 1998), Rattus norvegicus (Ginzburg et al., 1985) 
and Homo sapiens (Shiina et al., 2001). (N.B. * areas of variability). 
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3.4 Discussion 
 
 
This study was undertaken to determine if five novel analogues of trifluralin bind to the 
putative target, α-tubulin, in T. b. rhodesiense and whether the nature of the binding of 
each analogue differs. In addition, the extent of binding of each compound with β-
tubulin and mammalian tubulin was also investigated.  
 
The results of this study showed that five new analogues of trifluralin and commercial 
trifluralin strongly interacted with recombinant trypanosomal α-tubulin, inducing 
significant concentration dependent reductions in the intrinsic fluorescence. These 
compounds also produced distinctive binding affinities for recombinant trypanosomal 
α-tubulin. The structural differences between the five novel trifluralin analogues have 
led to a significant difference in the binding affinity of each compound with the three 
forms of tubulin. However, these differences did not alter the ability of these 
compounds to bind to trypanosomal α-tubulin.  
 
These results are consistent with the results of previous studies that showed that 
trifluralin binds to α-tubulin from T. gondii (Morrissette et al., 2004; Stokkermans et 
al., 1996). The large reduction observed in intrinsic fluorescence suggests that 
tryptophan residues are directly involved in the binding of these compounds to 
trypanosomal α-tubulin. Compound 1003 was the only analogue to bind with native rat 
brain tubulin, inducing a significant concentration dependent reduction in intrinsic 
fluorescence as a result of the C1 substituent of 4-morpholino. This suggests that 
tryptophan residues are also directly involved in the binding of this compound to rat 
brain tubulin. Compound 1003 bound more strongly to trypanosomal α-tubulin 
compared to rat brain tubulin as evidenced by the significant difference in their affinity  
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constants. This finding differs from previous reports that the dinitroaniline class of 
compounds do not bind to mammalian tubulin (Bajer and Mole-Bajer, 1986; Chan and 
Fong, 1990; Dow et al., 2002; Hess and Bayer, 1977; Hugdahl and Morejohn, 1993) 
and may suggest that dinitroanilines have the potential to cause toxicity in mammals. 
However, there appears to be no correlation between these findings and the results of an 
in vitro whole cell toxicity assay (unpublished data).  
 
Compounds 1007, 1008 and 1017 induced moderate, concentration dependent 
reductions in the fluorescence of trypanosomal β-tubulin. These moderate reductions 
suggests that tryptophan residues are indirectly involved in the binding of these 
compounds to trypanosomal β-tubulin. However, the affinity of binding was low for 
compounds 1007 and 1017 and compound 1008 demonstrated no binding affinity, 
which suggests that binding of these compounds to trypanosomal β-tubulin is weak and 
unstable. This result also suggests that compounds 1007 and 1017 may bind to both  α- 
and β-tubulin, which agrees with previous suggestions that the dinitroanilines act on 
both α- and β-tubulin in weeds (Anthony et al., 1998; Chan and Fong, 1994).  
 
Morrissette,  et al. (2004) has identified the putative binding site of common 
dinitroanilines on α-tubulin from T. gondii. This binding site was postulated to involve 
amino acid  residues Arg2 (R), Glu3 (E), Val4 (V), Trp21 (W), Phe24 (F), His28 (H), 
Ile42 (I), Asp47 (D), Arg64 (R), Cys65 (C), Thr239 (T), Arg243 (R) and Phe244 (F).  
All but two of these residues are present in the amino acid sequence of α-tubulin of T. 
brucei. The two residues absent in trypanosomal α-tubulin are Val4 (V), which is 
substituted for Ala4 (A) and Cys65 (C), which is substituted for Ala65 (A). The 
presence of the tryptophan residue Trp21 (W) in the dinitroaniline binding site in T.  
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gondii correlates with the strong quenching of intrinsic fluorescence of T. brucei α-
tubulin observed in this study. In addition, the T. brucei β-tubulin amino acid sequence 
shares only four common residues which may explain the low affinity of trifluralin 
analogues with trypanosomal β-tubulin.  
 
Mammalian  α-tubulin also shares the common residues found in the postulated 
dinitroaniline binding site in protozoal α-tubulin. The same two residues differ in 
mammalian and trypanosomal α-tubulin. The amino acid residue Val4 (V) is substituted 
for Cys4 (C) and Phe24 (F) is substituted for Tyr24 (Y) in mammalian α-tubulin. This 
may explain why compound 1003 bound with native rat brain tubulin but does not 
explain the selective action of the other four compounds for trypanosomal α-tubulin. 
The amino acid residues Arg2 (R), Glu3 (E), Trp21 (W), Phe24 (F), His28 (H) and 
Ile42 (I) are located in areas of the α-tubulin amino acid sequence where strong 
variations exist between trypanosomal and mammalian tubulin. It is possible that the 
binding site of these new analogues of trifluralin involves residues that are present in 
trypanosomal α-tubulin but absent in mammalian α-tubulin and that compound 1003 
binds to a different site on α-tubulin. 
 
A mechanism of action for common dinitroanilines has recently been proposed using 
computational techniques (Morrissette et al., 2004). When oryzalin was inserted into the 
α-tubulin binding site of T. gondii, it was situated beneath the N loop between 
protofilaments in the microtubule. It has previously been established that protofilament-
protofilament contact is mediated by N loops interacting with M loops of laterally 
adjacent subunits (Li et al., 2002). If oryzalin binds beneath the N loop, this interaction 
may be inhibited with the consequence of microtubule disruption. This differs from the  
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mechanism of action of other tubulin-binding compounds, such as colchicine and 
vinblastine which have been shown to interfere with tubulin assembly (Ravelli et al., 
2004; Gigant et al., 2005). 
 
Future studies should concentrate on establishing the molecular basis of the proposed 
trifluralin binding domain in trypanosomal α-tubulin. The single point mutation 
Thr239Ile and double mutation Ser165Ala/Thr239Ile in the α-tubulin amino acid 
sequence of T. gondii conferred dinitroaniline resistance (Morrissette et al., 2004).   
Similar approaches could be applied to the study of trifluralin binding to T. brucei α-
tubulin. All but two of the amino acid residues involved in dinitroaniline binding in T. 
gondii are shared by T. brucei and can provide a starting point for establishing their 
involvement in the trifluralin binding site by use of site-directed mutagenesis. Initially, 
single amino acids residues could be substituted followed by all relevant amino acid 
residues, in order to determine the effects this would have on the binding kinetics of 
these trifluralin analogues and also to determine the point at which a complete loss of 
trifluralin binding occurs.  
 
Differences in tubulin drug binding can be the basis for selective chemotherapeutic 
intervention against trypanosomal infection. The results of this study and others have 
demonstrated that differences in drug binding exist between protozoan parasite tubulin 
and mammalian tubulin and specifically trypanosomal tubulin and mammalian tubulin 
(Bhattacharya et al., 2004; MacRae and Gull, 1990; Werbovetz et al., 1999). Selective 
susceptibility is thought to be due to amino acid differences in tubulin structure between 
lower eukaryotes and mammals (Lacey, 1988). Trypanosomal tubulins have diverged 
significantly from the tubulins of mammalian species (Kimmel et al., 1985). A  
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comparison of the amino acid sequences of α-tubulin reveal that there is a high degree 
of homology between trypanosomal and leishmanial tubulin and only moderate 
homology between trypanosomal and rat tubulin. Therefore, it may be possible that 
these trifluralin analogues would also bind to leishmanial tubulin with similar affinity. 
However, previous studies suggest that this may not be the case and that small changes 
in amino acid sequence can have a dramatic influence on the binding of compounds to 
tubulins from different species (Bhattacharya et al., 2004).  
 
The tubulin used in this study was a homogenous and pure protein interacting with a 
chemically pure ligand under controlled conditions. Microtubules are in constant 
dynamic equilibrium undergoing the addition and substraction of soluble tubulin units at 
opposite ends of the developing tubule (Lacey, 1988). The formation and breakdown of 
microtubules are determined by the kinetics of assembly/disassembly that occurs at the 
plus end of the microtubule (MacRae, 1992). This dynamic behaviour of microtubules 
and the effect trifluralin analogues have on growing microtubules could be investigated 
using established microscope-based techniques (Grego et al., 2001; Viani et al., 2000). 
This would aid in the understanding of the mechanism of action these trifluralin have on 
trypanosomal microtubules. 
 
Understanding the nature of the interaction between trifluralins and trypanosomal 
tubulin is fundamental for the development of tubulin-specific anti-trypanosomatid 
compounds with selective activity, appropriate pharmacokinetic properties, and low 
human toxicity. The exact mechanism by which binding occurs is unclear, but might 
result from protein conformational changes induced by the binding of compounds to 
regions where amino acids differ between trypanosomal and mammalian tubulin. 
Trifluralin and its analogues possess strong binding with trypanosomal tubulin, which  
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provides further evidence that tubulin is a target for selective chemotherapeutic agents. 
Most notably, the results of this study have identified four trifluralin analogues (EPL-AJ 
1007, 1008, 1016 and 1017) as potential anti-trypanosomatid agents that warrant further 
development.   
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
Effects of Novel Trifluralin Analogues on the        
Ultra-Structure of Trypanosoma brucei. 
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4.1  Introduction 
 
 
A major characteristic of trypanosomes is a tightly defined, spatially co-ordinated 
cytoskeleton (Robinson et al., 1995), which is responsible for maintaining the shape and 
form of the cell and the modulation of cell shape between different life cycle stages 
(Hemphill et al., 1991). The main cytoskeletal components are the microtubular 
subpellicular corset, axoneme, basal body, paraflagellar rod (PFR), flagellum 
attachment zone and filaments responsible for attachment to insect tissues (Kohl and 
Gull, 1998). Microtubule-mediated events occur throughout the cell cycle. Cell shape 
and form are entirely dependent on the microtubular subpellicular corset, and 
polymerisation of new microtubules is an essential prerequisite for cell growth within 
the cell cycle (Robinson et al., 1995; Sherwin and Gull, 1989). Other microtubule 
dependent processes involving microtubule polymerisation/depolymerisation include 
kinetoplast segregation and repositioning (Matthews et al., 1995), basal body 
duplication, flagellar axoneme growth, mitosis and cytokinesis (Ploubidou et al., 1999).  
 
The effects of three common dinitroaniline analogues (oryzalin, ethalfluralin and 
trifluralin) have been shown to alter the cytoskeletal structure of Toxoplasma gondii in 
vitro  (Stokkermans et al., 1996). These compounds blocked nuclear division by 
inhibiting intranuclear spindle formation. Other cytoskeletal components were 
differentially affected depending on the analogue tested. In oryzalin-treated T. gondii, 
the subpellicular microtubules were absent and in ethalfluralin-treated T. gondii, large 
fragments of the inner membrane complex remained intact but the endoplasmic 
reticulum and nuclear envelope were highly distended (Stokkermans et al., 1996). 
Trifluralin and oryzalin have been shown to inhibit the polymerization of subpellicular 
microtubules of Leishmania sp. (Chan and Fong, 1990; Chan et al., 1991) and trifluralin  
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has been shown to induce the disassembly of subpellicular microtubules of Plasmodium 
sp. (Kaidoh et al., 1995). However, trifluralin treatment of T. cruzi in vitro induced 
many round, multi-flagellated forms without subpellicular or flagellar microtubule 
disruption (Bogitsh et al., 1999).  
 
It is hypothesised that if a compound binds to tubulin then it will inhibit the 
polymerization of tubulin into microtubules (Chan et al., 1991) or that microtubules will 
be depolymerised, which would ultimately result in microtubule disassembly and the 
loss of microtubules from the cell (Morrissette et al., 2004). These changes are likely to 
cause abnormalities in the cytoskeleton and possibly also in the nucleus and kinetoplast 
of trypanosomes.  
 
The positional ordering and segregation of the kinetoplast involves direct interaction 
with the microtubule cytoskeleton (Robinson and Gull, 1991). The kinetoplast and 
nucleus can be visualised using fluorescent cytological probes allowing the 
identification of the cell cycle stage. Cells early in the cell cycle possess a single 
kinetoplast and a single nucleus producing a 1K1N (1 kinetoplast, 1 nucleus) cell. As 
the cell cycle progresses the kinetoplast replicates and segregates in a discrete “S” phase 
prior to division of the nucleus to produce a 2K1N (2 kinetoplasts, 1 nucleus) cell. Cells 
then enter mitosis and the cell becomes 2K2N (2 kinetoplasts, 2 nuclei) and once 
cytokinesis occurs, cleaving the cell into two 1K1N siblings (Robinson et al., 1995).  
 
The effects dinitroanilines have on the ultrastructure of T. brucei are unknown. In this 
study, the interaction between new analogues of trifluralin and T. b. rhodesiense was 
investigated and an assessment of the effect of these compounds on the ultrastructure of  
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trypanosomes using light, fluorescence and transmission electron microscopy (TEM) 
was made.  
 
 
The aim of this study was: 
1.  To investigate the ultra-structural effects of new analogues of 
trifluralin on T. b. rhodesiense. 
  
Chapter 4. Ultra-Structural Effects of Trifluralin Analogues 
  99
4.2  Materials and Methods 
 
 
4.2.1  Novel Trifluralin analogues 
 
 
New trifluralin analogues EPL-AJ1003 (1003), EPL-AJ1007 (1007), EPL-AJ1008 
(1008), EPL-AJ1016 (1016), and EPL-AJ1017 (1017) were synthesized and supplied by 
Epichem Pty. Ltd. Albendazole and commercial trifluralin were also supplied by 
Epichem Pty. Ltd., and colchicine was purchased from Sigma (St Louis, MO). Stock 
solutions of these compounds were prepared in 100% dimethyl sulphoxide (DMSO) at a 
concentration of 1mM and stored in 50μl aliquots at –20
oC until required for use.  
 
 
4.2.2 Trypanosome  culture 
 
 
Blood stream forms of T. b. rhodesiense were cultured from cryopreserved stocks in 
HMI-9 media in 25cm
3 flasks according to Hirumi and Hirumi (1994) until a 
concentration of approximately 1 × 10
6 cells/ml was reached.  
  
 
4.2.3 Treatment  of  T. b. rhodesiense bloodstream forms with analogues of    
            Trifluralin. 
 
 
Cultured blood stream forms of T. b. rhodesiense were seeded in 48-well plates at a 
concentration of 1 × 10
6 cells/ml before the addition of their respective IC50 and IC70 
concentrations of compounds EPL-AJ1003, EPL-AJ1007, EPL-AJ1008, EPL-AJ1016, 
and EPL-AJ1017. The IC values in μM were determined from previous dose response 
curves (unpublished data) (Table 4.1). 
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Table 4.1 Concentrations of 5 trifluralin analogues that inhibit 50% (IC50) 
and 70% (IC70) of the growth of T. b. rhodesiense in vitro 
 
Compound   IC50 (μM)   IC70 (μM) 
EPL-AJ1003   0.2    0.3 
EPL-AJ1007   0.35    1.25 
EPL-AJ1008   0.2    2 
EPL-AJ1016   0.15    0.3 
EPL-AJ1017   0.1    0.25 
 
 
Control cultures of trypanosomes were incubated with only DMSO. Each culture was 
observed regularly using light microscopy over a 48hr period to determine the time 
point at which the trypanosomes were visibly affected. The cells were then processed 
for immunofluorescence or transmission electron microscopy.  
 
 
4.2.4 Immunofluorescence  study   
 
 
Glass slides were wiped with 70% ethanol to degrease them and then wiped with PBS 
(pH 7.2) to reduce their hydrophobicity. The slides were then wiped with 0.1% 
glutaraldehyde to enhance cell adherence. Two millilitres of culture medium containing 
T. b. rhodesiense was removed from each plate well and centrifuged at 1,000 × g for 
5min, resuspended in 200μl of HMI-9 media, smeared onto treated slides and air-dried 
for 30-45 min at room temperature. The slides were fixed in 4% paraformaldehyde and 
0.1% glutaraldehyde in PBS (pH 7.2) for 10min at room temperature. The aldehyde 
groups were then neutralized by washing the slides gently with 50µl of 100mM Glycine 
twice for 10min each time. The slides were then immersed gently into methanol and left 
to incubate for 2hr at -20
oC.  The slides were then gently removed from the methanol  
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and immersed gently into PBS (pH 7.2) two times for 5min each time to rehydrate the 
cells.  
 
The cells were incubated with 20μl of monoclonal anti-alpha tubulin antibody (TAT1) 
(Professor Keith Gull, Sir William Dunn School of Pathology, University of Oxford) for 
60min in a humid chamber at room temperature. The slides were washed twice for 5min 
each time in PBS (pH 7.2). Anti-mouse FITC-conjugated rabbit antibody (F-9137, 
Sigma, St Louis, MO) was added to the slides at a dilution of 1:100 in PBS (200μl total) 
and incubated for 60min in a humid chamber at room temperature in the dark. The 
slides were washed twice in PBS (pH 7.2) for 5min each time and then flooded with 
1μg/ml 4,6-diamidine-2-phenylindole (DAPI) in ddH2O for 4min to stain cellular DNA 
in the kinetoplast and nucleus and then washed with 200μL of 100mM HEPES (pH 7.5) 
twice for 5min. The slides were then treated with antifade reagents from the SlowFade
® 
Light Antifade Kit (Molecular Probes, Invitrogen) following the manufacturer’s 
instructions to reduce fading of the fluorescein. The slides were covered with a cover 
slip and sealed with white nail varnish and immediately viewed under an Olympus 
BX51 Photomicroscope (Olympus, Australia). 
 
 
4.2.5  Transmission electron microscopy 
 
 
The remaining culture medium containing T. b. rhodesiense was removed from each 
well and centrifuged at 1,000 × g for 10min, washed with 25ml of PBS (140mM NaCl, 
2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4, 80mM glucose, pH 7.4) and 
centrifuged again at 1,000 × g for 10min to obtain a pellet of trypanosomes for each 
treatment. Each pellet was fixed by incubation in a solution containing 4%  
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glutaraldehyde, 4% paraformaldehyde, 0.1% tannic acid in 0.1M cacodylate buffer (pH 
7.4) at room temperature for 2hrs. The samples were then washed three times by 
centrifugation at 1,000 × g for 10min in ddH2O. They were then post-fixed in a solution 
containing 1% osmium tetroxide and washed again in ddH2O as described above. The 
pellets were stained overnight by incubating in a solution containing 2% magnesium-
uranyl-acetate at 4
oC. The samples were then washed with ddH2O as described 
previously and dehydrated in a graded ethanol series of  30%, 50%, 70% for 30min each 
and 90% overnight. They were dehydrated again by immersion three times in absolute 
ethanol for 60min and then once overnight. The samples were then incubated in the 
following ratios of spurs resin:ethanol mixtures; 30%, 50%, 70% and 90% for 3hrs each 
before incubations in 100% spurs resin three times for 1hr each time. A final incubation 
in 100% spurs resin overnight was performed before the samples were embedded and 
polymerised in epoxy resin overnight at 60
oC. 70nm sections were cut and stained with 
lead citrate for 5min at room temperature and a solution containing 5% uranyl acetate in 
1% acetic acid for 30min at 60
oC. The processed and stained sections were examined 
using a Philips CM100 Biotwin transmission electron microscope (Philips Electronics 
NV, The Netherlands).  
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4.3 Results 
 
 
4.3.1 Immunofluorescence  Microscopy 
 
 
Untreated T. b. rhodesiense cells appeared to be morphologically normal maintaining 
their typical fusiform shape. Three stages of the trypanosome cell cycle were identified 
in these control samples. The DAPI-stained image revealed the presence of 1K1N and 
2K2N cells, with intact nuclei and kinetoplasts. The cells probed with TAT1 antibody 
stained positive for tubulin showing the outline of the cytoskeleton including the 
flagellum, which is attached along the whole length of each cell body (Figure 4.1).  
 
Examination of trypanosomes treated with the IC50 concentration of compound 1008 
showed some normal cells with typical morphology and some distended cells with 
abnormal morphology. DAPI staining revealed some normal 1K1N cells and some cells 
with no kinetoplast. Bright fluorescence was observed in the TAT1 antibody probed 
cells, clearly outlining the shape of the cytoskeleton including the flagellum, which is 
attached along the whole of the cell body in some cells but detached in others (Figure 
4.2). Trypanosomes that were treated with the IC70 concentration of compound 1008 
generally appeared distorted. DAPI staining revealed cells that were multi-nucleated 
and with multiple kinetoplasts. TAT1-probed cells revealed the presence of tubulin but 
distortion of the cytoskeleton including the flagellum, which is detached from the cell 
body (Figure 4.2).  
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Figure 4.1 Untreated T. b. rhodesiense processed and viewed using a) Phase contrast light 
microscopy, b) DAPI fluorescence, c) TAT1 probed fluorescence, d) merged images of DAPI 
fluorescence and TAT1 probed fluorescence. 
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Figure 4.2 T. b. rhodesiense treated with the IC50 concentration of compound 1008, processed 
and viewed using a) Phase contrast light microscopy, b) DAPI fluorescence, c) TAT1 probed 
fluorescence, d) merged images of DAPI fluorescence and TAT1 probed fluorescence. T. b. 
rhodesiense treated with the IC70 dose of compound 1008, processed and viewed using e) Phase 
contrast light microscopy, f) DAPI fluorescence, g) TAT1 probed fluorescence, h) merged 
images of DAPI fluorescence and TAT1 probed fluorescence. 
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Examination of trypanosomes treated with the IC50 concentration of compound 1003 
showed abnormal shaped cells that were often clustered together. DAPI staining 
revealed only 1K1N cells and TAT1 fluorescence staining showed the presence of 
tubulin but distortion of the cytoskeleton and the clustering of the cells (Figure 4.3). 
Trypanosomes that were treated with its IC70 concentration of compound 1003 also 
appeared distorted and clustered together. DAPI staining displayed distorted 
indistinguishable kinetoplasts and nuclei. TAT1 probed cells appeared as one large 
cluster of undefined cells (Figure 4.3).  
 
Trypanosomes treated with the IC50 concentration of compound 1016 generally 
appeared normal with some cells demonstrating a change in morphology similar to 
those induced by compound 1008. DAPI staining revealed mostly 1K1N cells 
containing intact kinetoplast and nucleus. TAT1 staining revealed cells with typical 
shaped cytoskeleton and intact flagellum (Figure 4.4). Trypanosomes treated with the 
IC70 concentration of compound 1016 were distorted with either detached or abnormally 
long flagellae. DAPI staining of these cells revealed damaged nuclei and damaged or 
repositioned kinetoplasts. TAT1-probed cells stained positive for tubulin which 
revealed the distorted shape of the cytoskeleton and flagellae that were completely 
detached from the cell bodies (Figure 4.4).  
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Figure 4.3 T. b. rhodesiense treated with the IC50 concentration of compound 1003, processed 
and viewed using a) Phase contrast light microscopy, b) DAPI fluorescence, c) TAT1 probed 
fluorescence, d) merged images of DAPI fluorescence and TAT1 probed fluorescence. T. b. 
rhodesiense treated with the IC70 dose of compound 1003, processed and viewed using e) Phase 
contrast light microscopy, f) DAPI fluorescence, g) TAT1 probed fluorescence, h) merged 
images of DAPI fluorescence and TAT1 probed fluorescence. 
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Figure 4.4 T. b. rhodesiense treated with the IC50 concentration of compound 1016, processed 
and viewed using a) Phase contrast light microscopy, b) DAPI fluorescence, c) TAT1 probed 
fluorescence, d) merged images of DAPI fluorescence and TAT1 probed fluorescence. T. b. 
rhodesiense treated with the IC70 dose of compound 1016, processed and viewed using e) Phase 
contrast light microscopy, f) DAPI fluorescence, g) TAT1 probed fluorescence, h) merged 
images of DAPI fluorescence and TAT1 probed fluorescence. 
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Trypanosomes treated with the IC50 concentration of compound 1007 appeared 
morphologically similar to those treated with the IC50 of compound 1003. Most cells 
generally appeared normal in shape but were clustered together. DAPI staining revealed 
only 1K1N cells. TAT1-probed cells appeared morphologically abnormal although most 
cells contained a normal cytoskeleton and flagellum (Figure 4.5). Trypanosomes treated 
with the IC70 concentration of compound 1007 were also generally irregular in their 
morphology. DAPI staining revealed damaged nuclei and kinetoplasts. TAT1-probed 
cells revealed the presence of tubulin but showed that cells were swollen and distended 
with detached flagella (Figure 4.5).  
 
Trypanosomes treated with the IC50 concentration of compound 1017 generally 
appeared normal but some abnormal cells were detected. TAT1-probed cells appeared 
swollen with detached flagella. DAPI staining revealed some 1K1N and some 
multinucleated cells (Figure 4.6). Trypanosomes treated with the IC70 concentration of 
compound 1017 generally appeared similar to those treated with the IC50 concentration. 
Many TAT1-probed cells emphasised the swollen morphology and detached flagella. 
DAPI staining revealed some cells that were either multinucleated with damaged 
kinetoplasts or the positioning of the kinetoplast had been altered, appearing closer to 
the nucleus (Figure 4.6). 
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Figure 4.5 T. b. rhodesiense treated with the IC50 concentration of compound 1007, processed 
and viewed using a) Phase contrast light microscopy, b) DAPI fluorescence, c) TAT1 probed 
fluorescence, d) merged images of DAPI fluorescence and TAT1 probed fluorescence. T. b. 
rhodesiense treated with the IC70 dose of compound 1007, processed and viewed using e) Phase 
contrast light microscopy, f) DAPI fluorescence, g) TAT1 probed fluorescence, h) merged 
images of DAPI fluorescence and TAT1 probed fluorescence. 
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Figure 4.6 T. b. rhodesiense treated with the IC50 concentration of compound 1017, processed 
and viewed using a) Phase contrast light microscopy, b) DAPI fluorescence, c) TAT1 probed 
fluorescence, d) merged images of DAPI fluorescence and TAT1 probed fluorescence. T. b. 
rhodesiense treated with the IC70 dose of compound 1017, processed and viewed using e) Phase 
contrast light microscopy, f) DAPI fluorescence, g) TAT1 probed fluorescence, h) merged 
images of DAPI fluorescence and TAT1 probed fluorescence.  
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4.3.2  Transmission Electron Microscopy 
 
 
Untreated trypanosomes displayed typical morphology when viewed using TEM. 
Although the sections stained darker than what is considered optimal, the main 
microtubular structures can be clearly visualised. Both the cell body and flagellum are 
limited by a three-ply plasma membrane which appears normal. The subpellicular 
microtubules appear intact with typical arrangement. The microtubules in the axoneme 
are also intact and appear to have the typical 9 + 2 arrangement of nine outer 
microtubule doublets with arms and two inner but separate microtubules (Figure 4.7).  
 
Trypanosomes treated with the IC70 concentration of compound 1008 appeared to be 
morphologically distorted. Figure 4.8 shows a cell with two flagella with disrupted 
plasma membranes and a degenerate subpellicular corset (Figure 4.8). The cytoplasm of 
the cell appears to contain membranous material and has no distinguishable organelles. 
The flagellum at the top of the image has a normal shape and an axoneme of typical 
arrangement but lacks a PFR. The flagellum at the bottom of the image contains a 
deformed axoneme and PFR. The subpellicular microtubules are either absent, leaving 
holes where there should be microtubules, or there are abnormally large gaps between 
microtubules (Figure 4.8).  
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a)      b) 
              
 
 
Figure 4.7 a) Transmission electron micrograph of a transverse section of an untreated T. b. 
rhodesiense cell b) high power of boxed area in a) showing paraflagellar rod (PFR), axoneme 
(AX), subpellicular microtubules (MT), and plasma membrane (PM). 
 
 
  
a )        b )  
                   
 
 
Figure 4.8 a) Transmission electron micrograph of a transverse section of a compound 1008 
treated T. b. rhodesiense cell b) high power of boxed area in a) showing degenerate plasma 
membrane (PM), flagellum with axoneme (AX) and no paraflagellar rod, holes in place of 
subpellicular microtubules (MT) and a flagellum (F) with deformed axoneme and paraflagellar 
rod.  
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Trypanosomes treated with the IC70 concentration of compound 1003 have similar 
morphological abnormalities observed in trypanosomes treated with compound 1008 
(Figure 4.8). These cells also contained unknown membranous material in their 
cytoplasm and had no distinguishable organelles. No microtubules could be visualised 
in the subpellicular array. Figure 4.9 shows a cell that has two flagella. The flagellum 
on the left of the image has an axoneme of typical arrangement but does not have a PFR 
and the flagellum on the right of the image has a malformed axoneme composition and 
no PFR. The plasma membrane is degenerate around the subpellicular corset and 
flagella. 
 
Trypanosomes treated with the IC70 concentration of compound 1016 appeared severely 
distorted. The flagella pocket is enlarged containing unknown fine tubular material with 
a detached flagellar pocket membrane. The flagellum has a malformed axoneme and no 
distinct PFR (Figure 4.10). The plasma membrane is disturbed in most areas of the cell 
and particularly surrounding the flagellum where it has fragmented. Microtubules are 
absent throughout the cell (Figure 4.10). 
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 a )       b )  
                    
 
Figure 4.9 a) Transmission electron micrograph of a transverse section of a compound 1003 
treated T. b. rhodesiense cell b) high power of boxed area in a) showing degenerate plasma 
membrane (PM) in the subpellicular corset containing no subpellicular microtubules, and 
flagellum with axoneme (AX) and no paraflagellar rod. 
 
 
 
a )       b )  
                  
 
Figure 4.10 a) Transmission electron micrograph of a transverse section of a compound 1016 
treated T. b. rhodesiense cell b) high power of boxed area in a) showing degenerate plasma 
membrane (PM) in the subpellicular corset with no subpellicular microtubules and flagellum (F) 
containing a degenerate plasma membrane, axoneme and paraflagellar rod. 
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Trypanosomes treated with the IC70 concentration of compound 1007 appeared distorted 
in a similar manner to trypanosomes treated with compound 1016 (Figure 4.10). The 
flagella pocket is enlarged and contains unknown fine tubular material. The flagellar 
pocket membrane is detached. The flagellum has a malformed axoneme containing no 
microtubules and no PFR. The plasma membrane is perturbed in most areas, 
particularly surrounding the subpellicular corset and flagellum where it is completely 
disintegrated. Few microtubules can be seen in the subpellicular membrane (Figure 
4.11).  
 
Trypanosomes treated with the IC70 concentration of compound 1017 appeared severely 
damaged. Cells contained large vesicles and membranous material in their cytoplasm. 
Most organelles have become degenerate and are indistinguishable, with the exception 
of the kinetoplast, which is clearly visible. The cell lacks a flagellum. The subpellicular 
corset is severely disfigured, containing no microtubules and the plasma membrane has 
disintegrated is most areas of the cell (4.12). 
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  a )       b )  
                      
 
 
 
Figure 4.11 a) Transmission electron micrograph of a transverse section of a compound 1007 
treated T. b. rhodesiense cell b) high power of boxed area in a) showing degenerate plasma 
membrane (PM) in the subpellicular corset containing no pellicular microtubules, and flagellum 
(F) with degenerate plasma membrane (PM) and containing no axoneme or paraflagellar rod. 
 
 
 
a )       b )  
                           
 
Figure 4.12 a) Transmission electron micrograph of a transverse section of a compound 1017 
treated T. b. rhodesiense cell b) high power of boxed area in a) showing degenerate plasma 
membrane (PM) in the subpellicular corset containing no subpellicular microtubules, degenerate 
organelles (O) and intact kinetoplast (K). 
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4.4 Discussion 
 
 
The purpose of this study was to investigate the morphological and ultrastructural 
effects that five novel analogues of trifluralin have on T. b. rhodesiense. The effect 
these new compounds have on microtubules was of particular interest because they have 
previously been shown to bind to recombinant trypanosomal tubulin (see Chapter 3). 
All compounds tested induced severe irreparable damage in T. b. rhodesiense, including 
perturbation of subpellicular microtubules, extensive cytoplasmic swellings, axoneme 
and paraflagellar rod (PFR) malformation, disfiguration around the flagellar pocket and 
membrane disintegration.  
 
To determine if tubulin and the cytoskeleton were affected by the test compounds, 
immunofluorescence was performed using monoclonal TAT1 antibody, which binds to 
tyrosinated trypanosomal α-tubulin. Treatment of cells with IC50  and IC70 
concentrations of each compound did not alter the ability of the TAT1 antibody to bind 
to tubulin as shown by the positive staining of tubulin. This demonstrates that the 
trifluralin binding and TAT1 antibody binding sites are not adjacent on tubulin. In 
addition, tubulin monomers do not appear to be affected by the binding of these 
compounds to them. If microtubules were depolymerised as a result of the compounds 
binding to tubulin, the tubulin monomers remained in the cell and were not degraded.  
 
The resulting fluorescence clearly outlines the cytoskeleton of the cells and emphasises 
the cytoskeletal abnormalities induced by treatment of the test compounds. At IC70 
concentrations of the five compounds, major cytoskeletal abnormalities were induced 
including the elongation and detachment of flagella. Compounds 1003, 1007 and 1017 
also induced these deformities at IC50 concentrations. These results are consistent with  
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reports that cell shape and form of trypanosomes are microtubule-dependent and 
polymerisation of new microtubules is a critical prerequisite for cell growth (Robinson 
et al., 1995; Sherwin and Gull, 1989).  
 
To determine trypanosome orientation, cell cycle stage and whether the nucleus and 
kinetoplast were affected, cells were treated with DAPI, which stains nuclear and 
kinetoplast DNA. DAPI staining of cells treated with the IC50 concentrations of 
compounds 1003, 1007, 1008 and 1016 revealed some 1K1N cells and cells with no 
kinetoplasts indicating that cell replication was abnormal or had ceased. Trypanosomes 
that were treated with the IC70 concentrations of compounds 1008, 1003, and 1017 were 
multi-nucleated and had multiple kinetoplasts indicating that the cells underwent 
mitosis before damage ensued and therefore, failed to complete cytokinesis. Previous 
studies using anti-microtubule drugs have shown that during drug treatment nuclear 
DNA synthesis occurs, which is then followed by an abnormal mitosis. Mitosis in the 
absence of a spindle is aided probably by interaction of the nuclear DNA with the 
nuclear envelope (Ploubidou et al., 1999). Trypanosomes treated with IC70 
concentration of compounds 1008, 1016 and 1007 contained damaged nuclei and 
kinetoplasts. Some trypanosomes treated with compounds 1016 and 1017 contained 
kinetoplasts that were positioned in close proximity to the nucleus. These cells also 
appeared round in shape and the flagellum was detached, which agrees with the findings 
of previous studies that disturbing the flagellum early in the cell cycle causes the cell to 
become morphologically abnormal and the kinetoplast to be repositioned closer in 
proximity to the nucleus (Kohl et al., 2003). These results differ from similar studies in 
T. brucei treated with the anti-microtubule rhizoxin, which produced 1K0N cells, called 
zoids (Robinson et al., 1995). Zoids were also described in L. donovani treated with  
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novel oryzalin analogues (Werbovetz et al., 2003). No zoids were found in this study. 
 
The most prominent effect of these compounds at IC70 concentrations was on the 
subpellicular microtubules that were missing from trypanosomes treated with 
compounds 1016, 1003 and 1017. The finding that trypanosomes treated with 
compounds 1007 and 1008 lacked microtubules agrees with previous electron 
microscopy studies that showed trifluralin-treated P. falciparam contained fragmented 
subpellicular microtubules (Kaidoh et al., 1995) and oryzalin-treated T. gondii were 
completely devoid of subpellicular microtubules (Stokkermans et al., 1996).  
 
Morphological events occurring early in the T. brucei cell cycle include duplication of 
basal bodies, formation of the new flagellum and building a new subpellicular array of 
microtubules. The precise duplication and positioning of cytoskeletal elements are 
necessary to ensure correct segregation to the two daughter cells (Gull, 1999). The 
process of building a new subpellicular array of microtubules involves the insertion of 
new microtubules between old microtubules (Sherwin and Gull, 1989). Subpellicular 
microtubules are cross-linked to each other and to the plasma membrane (Hemphill et 
al., 1991). The loss of subpellicular microtubules would therefore affect the plasma 
membrane.  
 
In the algae, Chlamydomonas, oryzalin has been shown to bind specifically to tubulin 
causing microtubules to depolymerise due to the tubulin-oryzalin complex binding to 
the growing end of the microtubule and thereby inhibiting microtubule growth. With 
depolymerisation of the microtubule from the minus end of the microtubule, the tubules 
become progressively shorter, eventually resulting in a complete loss of microtubules  
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(Hess and Bayer, 1977). Therefore, the most dynamic microtubules are the most 
affected. This would occur early in the cell cycle when new subpellicular microtubules 
are being formed. A number of treated trypanosomes that were observed contained 
holes in areas where microtubules should be or gaps between microtubules in the 
subpellicular array (Figure 4.8). It is a reasonable assumption that these are areas where 
new microtubules would ordinarily be assembled and that the binding of trifluralin 
analogues to tubulin have disrupted this process. The most structurally damaged cells 
were observed to lack subpellicular microtubules (Figures 4.9-4.11). It appears that the 
tubulin-binding of trifluralins prevented new microtubules from forming, causing the 
eventual destruction of the subpellicular array and subsequently arresting cell division.   
 
Some multi-flagellated trypanosomes were observed that appear to be similar to those 
observed in trifluralin-treated T. cruzi (Bogitsh et al., 1999) and oryzalin-treated 
Leishmania (Chan et al., 1991). Most of these flagella were structurally abnormal 
containing malformed axonemes with PFRs also malformed or absent. The axoneme is 
a highly organized structure composed of microtubules and the PFR is a highly ordered 
structure extending along and in close contact with most of the axoneme (Hemphill et 
al., 1991). It appears that the malformation of the axoneme and PFR is a direct result of 
the disassembly of microtubules in the axoneme. Mutant T. brucei cell lines have been 
produced using RNA interference (RNAi) (Bastin et al., 2000; Rusconi et al., 2005). 
These cells lack the ability to generate PFRs when the expression of an inverted PFR 
gene is induced, resulting in cell paralysis. RNAi could be applied in future studies 
whereby mutant T. brucei could be induced to cease axoneme assembly which would 
determine if this has a direct effect on the PFR and subsequent flagellum construction. 
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Non-flagellated forms of trypanosomes were also observed in compound 1017 treated 
cells by TEM. Non-flagellated forms have not been observed in dinitroaniline studies 
undertaken on any other organisms. However, Kohl (2003) showed that if the flagellum 
is affected early in the cell cycle, daughter cells will lack a flagellum.  
 
It is possible that these trifluralin analogues are affecting other targets in addition to 
microtubules or that microtubules are secondary targets. The drug-induced loss of 
subpellicular microtubules may be a secondary phenomenon that occurred as a result of 
perturbation of the plasma membrane and subsequent exposure of the subpellicular 
microtubules to environmental factors. However, trypanosomes treated with compounds 
1003, 1008 and 1016 had intact plasma membranes despite the presence of areas of 
complete microtubule loss. In addition, damage observed in the subpellicular array was 
almost always coupled with absent or malformed axoneme and paraflagellar rod, and 
where cells contained a degenerate subpellicular corset (completely devoid of 
subpellicular microtubules), severe flagellum malformation (with abnormal axoneme 
and absent PFR) or a lack of flagellum accompanied. Therefore, it is more likely that 
disruption of microtubules in this study is the primary mechanism for the subsequent 
disintegration of the cytoskeleton which arrested cell division and caused eventual lysis.  
 
Improvements in the visualisation of cytoskeletal structures of protozoan parasites using 
high-resolution field emission scanning electron microscopy (FESEM) has recently 
been achieved which enabled the study of the profile of subpellicular microtubules, the 
protein bridges cross-linking them as well as the filaments that form the PFR and its 
connection to the axoneme in T. brucei. In addition, the use of the high-resolution 
backscattered electrons (BSE) detector allowed immunolabelled tubulin in the T. brucei  
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cytoskeleton to be accurately mapped (Sant'anna et al., 2005). This approach could be 
applied to trifluralin-treated T. b. rhodesiense to provide further evidence that the 
primary target of these compounds is tubulin.  
 
It is not possible to unequivocally conclude that the disruption to microtubule 
architecture observed in this study is the direct result of the binding of the new 
trifluralin analogues to α-tubulin of trypanosomes. To achieve this further research is 
required to demonstrate that these inhibit polymerisation of tubulin into heterodimers 
and/or depolymerise heterodimers into monomers.  However, the potency of these novel 
analogues of trifluralin against T. b. rhodesiense clearly illustrates their potential use as 
chemotherapeutic agents and merits further investigation into their effects.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
 
Recombinant Tubulin from Trypanosoma brucei as a 
Candidate for a Vaccine to prevent                      
African Trypanosomiasis  
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5.1  Introduction 
 
 
There are currently no vaccines to prevent African trypanosomiasis and prospects for 
the development of a vaccine are considered poor (Seed, 2001). This is mainly due to 
the ability of trypanosomes to undergo antigenic variation to evade the host immune 
response and prolong their survival in the host (Barbet and McGuire, 1978; Donelson et 
al., 1998). The genetic basis of antigenic variation involves switching of the genes 
coding for the variable surface glycoproteins (vsg), which completely cover the surface 
of the cell (Pays and Nolan, 1998). Switching of the vsg genes occurs spontaneously at 
a frequency of 10
-7 and 10
-2 switches per cell per generation for laboratory-adapted and 
wild type strains, respectively (Pays and Nolan, 1998; Turner and Barry, 1989). Regular 
switching of the vsg eventually exhausts the host immune system, which is continuously 
being challenged to react to new surface determinants (Vanhamme and Pays, 1998). 
 
A number of studies have clearly demonstrated that different trypanosome cytoskeletal 
constituents can induce protective immunity in mice to a lethal challenge of T. brucei 
including: the microtubule-associated protein (MAP) p52 in combination with the 
glycosomal enzymes aldolase and glyceraldehyde-3-phosphate dehydrogenase (Balaban 
et al., 1995), the MAP p15 (Rasooly and Balaban, 2004) and native trypanosomal 
tubulin (Lubega et al., 2002a) In addition, Mkunza et al. (1995) were able to induce 
partial protection in cattle to natural infection with T. congolense and T. vivax by 
immunising them with a native flagellar pocket antigen purified from T. b. rhodesiense. 
Furthermore, mice immunised with native paraflagellar rod protein (PFR) (Wrightsman 
et al., 1995) and recombinant PFR protein (Luhrs et al., 2003) were fully protected 
when infected with T. cruzi.  
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This study aims to extend the results of a study conducted by Lubega, et al. (2002a), 
which showed that mice immunised with native tubulin purified from T. brucei survived 
a lethal infection with T. brucei.  To confirm that tubulin alone was responsible for the 
observed protection, the experiments were repeated using recombinant trypanosomal 
tubulin. 
 
 
The aims of this study were: 
 
1.  To determine if mice immunised with recombinant trypanosomal tubulin 
were protected from a lethal infection with T. b. rhodesiense. 
 
2.  To determine whether there is a significant difference in the immunity 
induced by α-tubulin, β-tubulin or a combination of both α- and β-
tubulin in mice.  
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5.2  Material and Methods 
 
 
5.2.1  Experimental animals and trypanosome isolates 
 
 
Experimental studies were performed with permission of the Murdoch University 
Animal Ethics Committee (AEC MU/R999/03), which complies with the guidelines 
from the National Health and Medical Research Council, Australia. A total of 30 
female, 6 week old, swiss ARC mice were obtained from the Animal Resource Centre, 
Murdoch University. The mice were provided with food and water ad libitum.  
 
Cryopreserved stabilates of T. b. rhodesiense (ATCC 30027) were stored in liquid 
nitrogen and propagated in two swiss ARC mice prior to infection of experimental 
animals. The mice were sacrificed and their blood collected when the parasitaemia was 
approximately 10
9 trypanosomes per ml of blood. Parasites were enumerated using a 
Neubauer haemacytometer. Blood was diluted with PBS (140mM NaCl, 10mM 
Na2HPO4, 2.7mM KCl, 1.8mM KH2PO4, pH 7.3) immediately prior to infection of 
experimental mice.   
 
 
 
5.2.2  Recombinant trypanosomal tubulin production 
 
 
The expression of α-tubulin and β-tubulin from T. b. rhodesiense as fusion proteins has 
been previously described (Chapter 2). The recombinant tubulin was maintained in PBS 
(pH 7.3) at a concentration of 1mg/ml and stored at -80
oC until required.  
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5.2.3  Immunization of mice 
 
 
Mice were allocated randomly into 6 groups of 5 mice. Each group was immunised by 
intraperitoneal (i.p.) injection with recombinant MBP-α-tubulin, GST-β-tubulin, MBP-
α-tubulin and GST-β-tubulin, recombinant MBP, GST, or PBS (pH 7.3) emulsified in 
Titermax
® adjuvant (Titermax USA, Inc., Georgia, USA) according to the schedule 
summarised in Table 5.1. Mice were monitored visually for any adverse reactions 
30min after vaccination. Any altered behaviour in the mice, such as hunching, lethargy, 
reluctance to move and/or recumbency was noted. 
 
Table 5.1 Schedule of immunisation of mice prior to infection with T. b. rhodesiense. 
 
Group     Dose (μg) at day                           
           1     8    21           
    PBS       -     -     -             
    MBP      40    20    20           
    GST      40    20    20           
  M B P - α     80    40    40           
  GST-β      80    40    40           
  M B P - α/GST-β   80   40   40   
                                                                                                                          
NB: PBS group were immunised with 20μl PBS emulsified with Titermax® 
 
All mice were infected with 10
3 T. b. rhodesiense (ATCC 30027) by intraperitoneal 
injection 29 days after the first immunisation was administered. Mice were observed 
visually twice daily after infection and parasitaemia monitored by microscopic 
examination of tail-tip blood for the presence of motile trypanosomes 3 days after 
infection and daily thereafter until mice died or became moribund. The level of 
parasitaemia was estimated using the matching method (Herbert and Lumsden, 1976).  
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Mice that developed high a terminal parasitaemia (i.e 10
8-10
9  trypanosomes/ml of 
blood) and/or showed signs of clinical illness were euthanased.  
 
 
 
5.2.4 Data  analysis 
 
 
The mean patent period was calculated using the number of days after infection when 
trypanosomes were first detected in blood and the length of survival was calculated 
from the number of days after infection when mice died or became moribund and were 
euthanased. The protection rate was calculated as the percentage of mice that survived 
until 30 days after infection and that did not have a detectable parasitaemia. The 
statistical significance of any differences was calculated using a one-way analysis of 
variance (ANOVA) and Tukey’s highly significant difference test with a 95% 
confidence limit.  
 
 
5.2.5  Evaluation of the antibody responses to trypanosomal tubulin 
 
 
Approximately 10
5 T. b. rhodesiense cultured according to Hirumi and Hirumi (1994) 
were centrifuged at 1,000 ×  g for 10min, washed with 1ml of PBS (pH 7.3) and 
centrifuged again at 1,000 × g for 10min. The pellet of cells was resuspended in 100μl 
of PBS (pH 7.3) and freeze-thawed 3 times to disrupt the cells. The total soluble protein 
fraction was collected from the supernatant after centrifuging at 12,000 × g for 1min 
and stored at -80
oC until required.  
 
Blood was collected into heparinised capillary tubes from the tails of two mice from 
each group on days 7, 20, and 28 (i.e. after each immunization). Capillary tubes were  
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centrifuged at 12,000 × g and the plasma extracted. The plasma was pooled according to 
vaccine group and day of collection and stored at -80
oC until required. 
 
Western Blot analysis was performed (as previously described in Chapter 2) using 
pooled plasma diluted 1:100 and the total soluble protein extracts of T. b. rhodesiense to 
determine the presence of anti-tubulin antibodies after each vaccine boost.  
 
 
5.3  Results    
 
 
5.3.1 Immuno-protection  study 
 
 
Trypanosomes were detected in the blood of all mice 3 to 4 days following infection 
with T. b. rhodesiense. No mice survived infection with T. b. rhodesiense therefore, the 
protection rate was 0. The mean patent period was significantly higher in the group of 
mice immunised with GST-β-tubulin compared to all other treatment groups (p < 0.05) 
(Table 5.2). There was no significant difference between the mean patent period 
observed in mice immunised with PBS, MBP, GST, MBP-α-tubulin and MBP-α-
tubulin/GST-β-tubulin (Table 5.2). Mice immunised with MBP-α-tubulin, GST-β-
tubulin and MBP-α-tubulin/GST-β-tubulin survived significantly longer compared with 
mice immunised with PBS alone (p < 0.05) (Table 5.2). There was no significant 
difference in the length of survival between the groups vaccinated with the recombinant 
proteins. 
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Table 5.2  Mean patent period (days) and length of survival (days) of immunised mice          
                  following infection with T. b. rhodesiense.  
 
 
      Vaccine Group          n     Mean patency (95% C.I.)     Mean survival (95% C.I.)      
          PBS                   5            3.0            (3.0, 3.0)     3.8           (3.5, 4.1)   
MBP                   5            3.0            (3.0, 3.0)     4.2         (3.4, 5.0)   
GST                        5            3.0            (3.0, 3.0)     4.4         (3.9, 4.9)   
MBP-α                  5            3.0            (3.0, 3.0)     5.1 *        (4.0, 6.2)   
GST-β                   5            4.0 *         (3.1, 4.9)     5.3 *        (4.6, 6.0) 
MBP-α/GST-β         5            3.2            (2.4, 4.0)     5.0 *        (4.4, 5.6) 
 
          * value significantly higher than PBS control (p < 0.05) 
 
 
 
 
5.3.2  Evaluation of the presence of anti-tubulin antibodies in the plasma of   
immunised mice 
 
 
SDS-PAGE analysis of a crude extract of soluble protein from T. b. rhodesiense 
revealed the presence of proteins ranging from approximately 25kDa to 250kDa in size 
(Figure 5.1). Plasma collected from mice immunised with recombinant α- and β-tubulin 
fusion proteins contained antibodies that recognized a 55kDa band that corresponds to 
tubulin as shown in the Western Blots (Figures 5.2, 5.3 and 5.4). The amplitude of the 
antibody reactions appeared to increase after each immunisation as evidenced by an 
increase in the intensity of the colour reaction. Plasma collected from the PBS, MBP 
and GST control groups did not recognize any antigen in the soluble fraction of T. b. 
rhodesiense (Figure 5.5). 
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Figure 5.1 SDS-PAGE gel image illustrating the total soluble protein extracted 
from T. b. rhodesiense. 
 
 
                       
                                        a                               b                               c 
 
Figure 5.2 Western Blot analysis of the total soluble protein extracted from T. b. 
rhodesiense using pooled plasma collected from mice a) 7, b) 20 and c) 28 days 
after immunisation with MBP-α-tubulin. 
 
 
 
                    
                                                     a                               b                            c 
 
Figure 5.3 Western Blot analysis of the total soluble protein extracted from T. b. 
rhodesiense using pooled plasma collected from mice a) 7, b) 20 and c) 28 days 
after immunisation with GST-β-tubulin. 
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           a                             b                           c 
 
Figure 5.4 Western Blot analysis of the total soluble protein extracted from T. b. 
rhodesiense using pooled plasma collected from mice a) 7, b) 20 and c) 28 days 
after immunisation with MBP-α-tubulin and GST-β-tubulin. 
 
 
 
 
 
 
 
                   
           a                                b                         c 
 
 
Figure 5.5 Western Blot analysis of the total soluble protein extracted from T. b. 
rhodesiense using pooled plasma collected from mice 28 days after immunisation 
with a) PBS, b) MBP and c) GST. 
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5.4 Discussion 
 
 
The aim of this study was to determine if recombinant trypanosomal tubulins were able 
to elicit protective immunity in mice. The efficacy of the recombinant trypanosomal 
tubulins as vaccine candidates was assessed by monitoring the survival and parasitaemia 
of immunised mice following challenge with a lethal infection of T. b. rhodesiense. 
Although all the mice vaccinated with recombinant tubulin developed patent 
parasitaemias and did not survive, they were partially protected by GST-β-tubulin 
because their patency period and length of survival were significantly longer than the 
controls (Table 5.2). Furthermore, the plasma taken from mice immunised with 
recombinant trypanosomal tubulin contained antibodies that recognized native tubulin 
from the T. b. rhodesiense total soluble extract.  
 
Most vaccines use proteins that are present on the surface of the target organism 
because these proteins are most accessible to the host immune response. However, 
vaccines using vsg are ineffective because trypanosomes undergo antigenic variation 
(Barbet and McGuire, 1978; Donelson et al., 1998). Despite this, cattle immunised 
intravenously with 10
7 irradiated T. brucei were fully protected against homologous 
infection 14 days later and most of the antibodies elicited by the irradiated 
trypanosomes were specific for vsg proteins. (Morrison et al., 1982). However, only 1 
of 3 cattle given weekly doses of 10
9 irradiated T. b. rhodesiense was immune to 
homologous infection 7 days after the third dose (Wellde et al., 1973).     
 
The results of this study support the findings of Lubega, et al (2002a), which 
demonstrated that mice immunised with native trypanosomal tubulin survived a lethal 
infection with T. brucei.  The basis of this protection is not clear because there is no  
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prior evidence that host antibodies are internalised by trypanosomes. However, Lubega 
et al. (2002b) further showed that serum from mice immunised with tubulin inhibited 
the growth of T. brucei in vitro. This would suggest that there is a mechanism for 
endocytosis of host immunoglobulins. It has been suggested that the flagellar pocket 
may be involved in the internalisation process, since antibodies that become bound to 
the trypanosome surface migrate to the region of the flagellar pocket by patching (Gull, 
2002). Once internalized, antibodies against tubulin may compromise the mitotic 
spindle, axoneme, or cytoskeleton, which would have trypanocidal effects. However, 
recent studies have shown that surface-bound antibodies can be internalised and then 
degraded within the endosomal system, providing another mechanism by which 
bloodstream forms of T. brucei can evade the host immune response. This process 
involves two trypanosomal Rab proteins, TbRAB11 and TbRAB4, which are central 
components of vesicle transport systems (Pal et al., 2003). It is likely that this 
mechanism played a role in preventing the full protection of immunised mice from T. 
brucei infection.  
 
Mice immunised with recombinant tubulin mounted strong antibody responses against 
native trypanosomal tubulin, although this was not sufficient to protect the mice from 
lethal infection. Lubega et al (2002a) showed that the passive transfer of anti-tubulin 
antibodies to naïve mice conferred 80% protection, suggesting that the basis for the 
protection is humoral. These findings differ from studies on T. cruzi that showed that 
protective immunity in mice immunized with PFR proteins is associated with a TH1-
type response (Miller et al., 1996). It is more likely that both humoral and cell-mediated 
is required to provide full immuno-protection against trypanosomal infection.  
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There was no significant difference between the lengths of survival between the three 
vaccine groups, although the patent period was significantly longer for the GST-β-
tubulin group compared to the MBP-α-tubulin and MBP-α-tubulin/GST-β-tubulin 
groups. The reason for this difference is unclear although it is possible that the relative 
concentration of each protein differed because GST is approximately half the molecular 
weight of MBP. It is possible that the relatively low dose of protein and short 
immunisation schedule used in this study was not sufficient to provide protective 
immunity. The quantity of recombinant protein used in this study was based on Lubega, 
et al (2002a) where an initial dose of 40μg of native trypanosomal tubulin was followed 
by two boosts of 20μg of the same protein. The amount of recombinant tubulin used in 
this study was twice that used by Lubega, et al (2002a) to make allowance for the 
presence of the fusion partner. Vaccine studies using native PFR from T. cruzi 
demonstrated that the optimal dose for producing 100% immuno-protection in mice was 
an initial dose of 40μg followed by 2 boosts of 20μg (Miller et al., 1996). Miller et al. 
(1996) also demonstrated that a 50% reduction in the amount of protein used resulted in 
failure to protect mice infected with T. cruzi because there was insufficient humoral 
immunity to clear infection. The presence of the fusion partner may also have masked 
antigenic epitopes. However, previous studies using recombinant proteins as GST or 
MBP fusions have shown that the fusion partner does not interfere with the 
development of protective immunity in animal models against infection with 
Schistosoma mansoni (Schechtman et al., 2001), Plasmodium sp. (Kang et al., 1998) 
(Oliveira-Ferreira et al., 2004) and T. gondii (Lunden et al., 1997). Furthermore, it has 
been reported that fusion partners can be advantageous in vivo because they may protect 
the target protein from intracellular proteolysis (Sorensen and Mortensen, 2005). 
However, there are insufficient data from this study to confirm or reject this possibility.  
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Future studies could be improved by using pure recombinant α- and β-tubulin without a 
fusion partner or by using different expression systems that utilise smaller fusion 
partners such as histidine.  
 
It may be possible that other immunogenic contaminants were present in the fusion 
protein preparations and that they are partially responsible for the results observed. 
However, the recombinant tubulin fusion proteins MBP-α-tubulin and GST-β-tubulin 
used in this study were purified and analysed for purity (see Chapter 2). A single band 
was produced for each fusion protein; 100kDa for MBP-α-tubulin and a 75kDa sized 
band for GST-β-tubulin. Immuno-blotting confirmed the presence of both the fusion 
protein tag and the accompanying tubulin subtype for each fusion protein (see Chapter 
2). It is possible that other more sensitive staining methods, such as silver staining, 
could reveal trace amounts of contaminants of different molecular weights. However, 
the immune sera collected from the vaccinated mice only recognized a protein 
approximately 55kDa in size, which is equivalent to the molecular weight of tubulin. It 
is unlikely that a contaminant of equal size to tubulin could be responsible for the partial 
immuno-protection observed in the mice. This is because the recombinant proteins used 
to vaccinate the mice were produced in bacterial cells and purified using affinity 
chromatography that is specific for the two fusion protein tags.  
 
It has been suggested that the choice of adjuvant can have a significant effect on the 
level of protection provided by a vaccine (Daly and Long, 1996) and this should be 
empirically investigated when optimising vaccine conditions in animal models. 
Titermax
® was chosen for this study because it was reported to be as effective as 
Freunds complete adjuvant (FCA) without the toxic effects that FCA can induce in mice  
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(Bennett et al., 1992). It has also been suggested that the route of inoculation may affect 
vaccine efficacy (Daly and Long, 1996). However, Lubega et al. (2002a) successfully 
immunised mice by intraperitoneal administration of native trypanosomal tubulin. 
Future studies to optimise vaccine efficacy should evaluate the use of alternative 
adjuvants, such as alum, FCA and saponin and alternative routes of administration, such 
as intramuscular and subcutaneous.  
 
Suppression of the proliferative T-cell response to trypanosomal antigens has previously 
been reported (Alcina and Fresno, 1985; Charoenvit et al., 1981; Corsini et al., 1977; 
Masake et al., 1981), although the role of the T-cell response to T. brucei infection 
remains unclear to date. In this study, the humoral response was not sufficient to 
provide full protection in mice infected with T. brucei and so future vaccine studies 
should concentrate on inducing both a humoral and cell-mediated immune response. 
The next logical step would be to investigate tubulin DNA as a vaccine as either naked 
plasmid DNA, tubulin DNA delivered in a viral vector or by following a DNA-priming 
protein-boosting immunization regime. Use of tubulin DNA as a potential vaccine could 
be explored in future studies. Studies using an adenoviral vector containing the gene 
coding for MAP p15 was found to generate strong CD8
+ T-cell proliferation and 
provided full immuno-protection in mice challenged with a lethal infection of T. brucei 
(Rasooly and Balaban, 2004). It has previously been established that immunisation 
using “naked” plasmid DNA (i.e. DNA that is not associated with any delivery vehicle 
such as virus) provides an effective activator of both humoral and cellular immune 
responses and has been used in preclinical animal models for viral, bacterial and 
parasitic diseases (Donnelly et al., 1997), although has not been trialled against T. 
brucei infection. An alternative immunisation protocol could use a DNA-prime protein-
boost immunization schedule consisting of trypanosomal tubulin DNA followed by  
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recombinant trypanosomal tubulin protein. DNA-priming protein-boosting 
immunization takes advantage of the ability of DNA immunization to guide the immune 
responses toward a cell-mediated response. This method has successfully been applied 
in studies using PFR protein 2 from L. mexicana as a vaccine against homologous 
infection in hamsters (Saravia et al., 2005). Similar studies in T. cruzi, found that 
although a DNA prime of the catalytic domain of trans-sialidase (TS) followed by 
recombinant TS protein boost generated a strong cell-mediated response, it did not 
provide immuno-protection against T. cruzi infection in mice (Vasconcelos et al., 2003).  
 
A successful recombinant vaccine based on tubulin would be a significant advancement 
in the control of human and animal African trypanosomiasis. This study has provided 
further evidence that tubulin is a potential target for the development of a vaccine to 
prevent African trypanosomiasis. However, further investigation is required to optimise 
vaccine preparations and maximise protective immune responses against recombinant 
tubulin. 
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The purpose of this study was to explore if tubulin, in particular α-tubulin, from T. b. 
rhodesiense are valid targets for the development of new therapeutic agents for the 
treatment or prevention of human African trypanosomiasis (Sleeping Sickness).  The 
impetus for this study came from the fact that current treatment regimes for 
trypanosomiasis are unsafe, expensive, difficult to administer and often ineffective.   
 
The production of recombinant trypanosomal α- and β-tubulin proteins in bacterial 
expression systems enabled the purification of large quantities of soluble protein, free 
from impurities, post-translational modifications and microtubule-associated proteins, 
making them suitable for drug-binding and vaccine studies. These fusion proteins were 
successfully used to determine the binding kinetics of several compounds to 
trypanosomal and mammalian tubulins. Ideally this study would have been completed 
with only the protein of interest without their fusion partners but this was not possible. 
The MBP and GST fusion partners did not appear to have affected the drug-binding 
studies conducted in this project although they may have impeded access of the host 
immune responses to the tubulin monomers in vivo during the vaccine studies.  
 
There are no published reports of studies using recombinant trypanosomal tubulins and 
few reports of the use of native trypanosomal tubulins to determine the characteristics of 
binding of the dinitroanilines.  Five new analogues of trifluralin were shown to bind 
strongly to recombinant trypanosomal α-tubulin and only 3 compounds bound weakly 
to recombinant trypanosomal β-tubulin.  Only one compound was shown to bind with 
any affinity to native rat tubulin probably as a result of the C1 substituent of 4-
morpholino.  This demonstrates the dramatic effects that alterations in the chemical 
composition of trifluralin can have on specificity of their binding. The mechanism by  
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which binding occurs is unknown although it appears that the binding site of these new 
analogues of trifluralin directly involves tryptophan residues and other residues that are 
present in trypanosomal α-tubulin but absent in mammalian α-tubulin.  Future studies 
will need to concentrate on determining the mechanism of binding and to determine 
their effects on the growth of microtubules.  
 
The novel trifluralin analogues induced severe irreparable damage to bloodstream forms 
of  T. b. rhodesiense with the most prominent effect being the disruption to the 
subpellicular array.  This dramatic effect on the cells is strong evidence that trifluralin 
and its analogues target tubulin and disrupt microtubule formation. However, further 
work is required to prove that these compounds inhibit the polymerisation of tubulin 
before we can unequivocally conclude that tubulin is their primary target.  
 
Past attempts to develop vaccines to prevent trypanosomiasis have failed mainly 
because of the parasites ability to evade the host immune response.  Recombinant 
trypanosomal tubulin induced a humoral response in vaccinated mice but was 
insufficient to prevent infection. There is now a need to optimise the vaccine 
preparation used in this study and further evaluate the mechanism of the immune 
protection observed in this study.  
 
Tubulin is a valid chemotherapeutic target for nematocidal and antiprotozoal drugs.   
This study has shown that tubulin offers a potential new target for the development of 
novel chemical and immunological therapeutic agents for the treatment and prevention 
of trypanosomiasis. 
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